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Summary 
 
Aims and methods: This thesis investigated the prevalence of and trends in 
antimicrobial resistance in pneumococci in Finland, determined the genetic 
basis of macrolide resistance and evaluated the level of telithromycin non-
susceptibility prior to its widespread usage. In addition, the clonality of 
telithromycin-resistant and penicillin-resistant isolates was examined. The 
study includes two sets of bacterial isolates: the first set consisted of 1007 
non-invasive and invasive pneumococci collected in 2002 and the second set 
of isolates included all invasive pneumococci (n = 3571) collected in Finland 
in 2002-2006. Agar plate dilution in 5% CO2, CLSI broth and disk diffusion 
methods were used for antimicrobial susceptibility testing. PCR was used to 
detect macrolide resistance genes and pyrosequencing to search for ribosomal 
mutations in domains V and II of 23S rRNA, and in genes encoding 
ribosomal proteins L4 and L22. The clonality of the bacteria was investigated 
with PFGE and multilocus sequence typing (MLST). 
 
Results: Of the 1007 pneumococci collected in 2002, 21.5%, 12.1%, and 
14.4% were non-susceptible to erythromycin, penicillin and tetracycline, 
respectively. Multiresistance was detected in 10.5% of the isolates. Only 
0.1% of the isolates were non-susceptible to ceftriaxone (non-meningitis 
breakpoint) and <1.5% to fluoroquinolones. Two isolates were non-
susceptible to linezolide. In 2002-2006, erythromycin resistance increased 
from 16% (2002) to 28% (2006) (Poisson regression, p < 0.0001), penicillin 
non-susceptibility from 8% to 16% (< 0.0001) and penicillin resistance from 
0.8% to 3.7% (p = 0.03). Tetracycline resistance remained stable (~10%), as 
did the proportion of multiresistant isolates (~5%). Levofloxacin and 
ceftriaxone resistance was rare. Serotypes 14, 9V, 6B, 19F and 19A were 
the most frequently non-susceptible to erythromycin or penicillin. In both 
sets of collections of pneumococci, the highest prevalence of erythromycin 
resistance was among isolates derived from 0- to 2-year-old children: in 
2006, 45.8% of isolates were resistant to erythromycin in this age group.  
 
In 2002, disk diffusion testing revealed 26/1007 (2.6%) pneumococcal 
isolates that produced one to several clearly visible colonies inside the 
growth inhibition zone, indicating heterogeneous resistance to telithromycin. 
The telithromycin MIC50 and MIC90 of these isolates were 2 and 4 mg/L 
(range 0.063 to 8 mg/L), respectively, when measured by the agar dilution 
method, but with CLSI broth microdilution in a normal atmosphere the 
MIC50 and MIC90 were 0.125 and 1 mg/L, respectively (range 0.063 – 2 
mg/L). The telithromycin MIC50 and MIC90 of the zone isolates (isolated 
from the colony growing inside of the inhibition zone) was 32 mg/L and 64 
mg/L, respectively, according to the agar dilution method in 5% CO2, whilst 
they were 4 and 8 mg/L with CLSI broth microdilution in ambient air. This 
type of telithromycin resistance has not previously been described. All such 
isolates were erm(B) positive and two of them also carried mef(E), but the 
exact underlying mechanism of telithromycin resistance remained 
unresolved. Telithromycin resistant isolates had seven distinct sequence 
types, of which ST193 was the most frequent (n = 19). Other sequence types 
were 133, 273, 271, 2248, 2306 and 2307. PFGE results were in 
accordance with the MLST results. ST193 isolates were all 19A serotype 
variants of the PMEN clone Greece21-30, while ST273 is a representative of 
the PMEN global clone Greece6B-22 and ST271 is a single locus variant of a 
multi-drug-resistant Taiwanese19F ST236 clone. 
 
Among penicillin resistant isolates in 2002-2006, a total of 25 sequence types 
were found that distributed into ten clonal lineages (clonal complexes, CC). The 
most common clonal complex was CC156, accounting for 61% of all penicillin-
resistant isolates, followed by CC271 (10% of the isolates) and CC81 (9%). The 
majority of the penicillin-resistant pneumococci in this study were 
representatives of single to triple locus variants of the following PMEN clones: 
Spain9V ST156, Taiwan19F ST236, Spain23F ST81, and England14 ST9.  
 
In 2002, the most frequent macrolide resistance gene was the mef gene 
(49%), followed by erm(B) (41%). A double mechanism [mef(E)+erm(B)] 
was detected in 5 (2.3%) isolates. Of the mef genes, 89% had the mef(E) 
subclass and 11% had mef(A). Mutation was detected in 16 isolates, of 
which 14 isolates (6.4%) had no other known resistance factor. Six new 
ribosomal protein mutations were recorded in this study. Of these, four 
mutations were in the L4 protein (68E69, 68GQK69, T94I, V205G) and two in the 
L22 protein (R22C, A101P). In 2002-2006 the macrolide gene distribution was 
similar: the mef gene was detected in 56% of the investigated isolates (n = 
223), while erm(B) was present in 31% and both mef(E) and erm(B) in two 
isolates (0.9%). Of the mef-positive isolates that were further investigated (n 
= 60), 72% had mef(E) and 28% mef(A).  
 
Conclusions: The main observation of this thesis was the presence of 
heterogeneous telithromycin resistance among pneumococci carrying erm(B). 
Such isolates harbour a minor population of bacterial cells capable of 
expressing high level telithromycin resistance in vitro, which may be 
clinically significant. Because CLSI broth microdilution does not favour the 
detection of this resistance type, the disk diffusion susceptibility testing of 
erm(B)-positive pneumococci is recommended. Due to the high prevalence of 
resistance, macrolides cannot be recommended as the first line drugs for the 
treatment of pneumococcal infections. Apart from macrolide resistance, the 
proportion of penicillin non-susceptible isolates is rising. 
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Tiivistelmä 
 
Tavoitteet ja metodit: tässä tutkimuksessa selvitettiin pneumokokkibakteerin 
mikrobilääkeresistenssin esiintyvyyttä ja trendejä Suomessa ja testattiin kantojen 
herkkyyttä telitromysiinille ennen sen laajamittaista käyttöönottoa. Lisäksi tutkittiin 
makrolidiresistenssimekanismeja sekä resistenttien pneumokokkien klonaalisuutta. 
Tutkimus perustuu kahteen aineistoon, joista ensimmäinen käsittää 1007 pneumokokki-
kantaa, jotka on kerätty vuonna 2002. Toinen aineisto käsittää kaikki Suomessa eristetyt 
invasiiviset pneumokokit vuosilta 2002–2006 (n = 3571). Mikrobilääkeherkkyystestaus 
suoritettiin maljalaimennosmenetelmällä 5 % hiilidioksidiatmosfäärissä. Lisäksi 
käytettiin CLSI:n nestelaimennos- ja kiekkodiffuusiomenetelmiä. Makrolidiresistenssi-
geenejä etsittiin PCR-menetelmällä. Pyrosekvensointia ja sekvensointia käytettiin 
ribosomaalisten mutaatioiden osoittamiseen (domeeni V, 23S rRNA, ja ribosomaaliset 
proteiinit L4, L22). Bakteerien klonaalisuutta tutkittiin PFGE ja MLST – tekniikoilla.  
Tulokset: Vuonna 2002 kerätystä 1007 pneumokokkikannasta 21.5 %, 12.1 %, 14.4 % 
ja 26.8 % oli resistenttejä tai herkkyydeltään heikentyneitä erytromysiinille, penisilliinille 
ja tetrasykliinille. Kannoista 1.5 % oli multiresistenttejä. Vain 0.1 % kannoista oli 
herkkydeltään heikentyneitä keftriaksonille (ei-meningiitti raja-arvo) ja <1.5 % 
fluorokinoloneille. Kahden kannan herkkyys linetsolidille oli heikentynyt. Vuosina 
2002–2006, erytromysiiniresistenssi nousi 16 %:sta (2002) 28 %:iin (2006) (Poisson 
regressio, p < 0.0001). Penisilliinille ei-herkkien kantojen osuus nousi 8 %:sta 16 %:iin 
(< 0.0001) penisilliinille resistenttien kantojen osuus 0.8 %:sta 3.7 %:iin (p = 0.03). 
Tetrasykliiniresistenssi pysyi tasaisena (~10 %), kuten myös multiresistenttien kantojen 
osuus (~5 %). Levofloksasiini- ja keftriaksoniresistenssi oli harvinaista. Serotyypeistä 14, 
9V, 6B, 19F and 19A olivat useimmin penisilliinille tai erytromysiinille resistenttejä. 
Molemmissa aineistoissa korkein makrolidiresistenssi havaittiin pneumokokeissa, jotka 
olivat eristetty 0-2 vuotiailta lapsilta. Vuonna 2006 tässä ikäryhmässä jo 46 % 
pneumokokeista oli resistentteijä erytromysiinille.   
Vuonna 2002 kerätyistä pneumokokeista 26 (2.6 %) kannassa todettiin 
kiekkoherkkyystestauksessa heterogeeninen resistenssi telitromysiinille. Näillä 
kannoilla telitromysiinikiekon estovyöhykkeen sisällä havaittiin selkeitä pesäkkeitä, 
joiden lukumäärä vaihteli. Maljalaimennosmenetelmällä näiden kantojen telitromysiini 
MIC50 ja MIC90 arvot olivat vastaavasti 2 ja 4 mg/L (vaihteluväli 0.063-8 mg/L), mutta 
CLSI:n nestelaimennos-menetelmällä huoneilmassa 0.125 ja 1 mg/L (vaihteluväli 
0.063 – 2 mg/L). Estovyöhykkeen sisältä eristetyissä ns. vyöhykekannoissa 
maljalaimennosmenetelmän telitromysiini MIC50 ja MIC90 arvot olivat 32 mg/L and 64 
mg/L, mutta 4 ja 8 mg/L CLSI:n nestelaimennosmenetelmällä. Aiemmin tällaista 
telitromysiiniresistenssiä ei ole dokumentoitu. Kaikilla telitromysiini-resistenteillä 
kannoilla oli erm(B) makrolidiresistenssigeeni ja lisäksi kahdella oli myös mef(E). 
Telitromysiiniresistenssin tarkempi mekanismi ei kuitenkaan tutkimuksissa selvinnyt. 
Telitromysiiniresistentit pneumokokit olivat seitsemää eri sekvenssityyppiä. Yleisin 
sekvenssityyppi oli ST193 (n = 19). Muita sekvenssityyppejä olivat 133, 273, 271, 
2248, 2306 and 2307. PFGE tulokset vastasivat MLST tuloksia. ST193 kannat olivat 
kaikki serotyyppiä 19A ja ovat siten PMEN kloonin Greece21-30 variantteja. ST273 
edustaa maailmanlaajuisesti levinnyttä Greece6B-22 kloonia, ja ST271 eroaa yhden 
lokuksen osalta multiresistentistä Taiwanese19F ST236 – kloonista. 
Vuonna 2002–2006 penisilliiniresistenttit kannat olivat 25 eri sekvenssityyppiä, jotka 
muodostivat 10 klonaalista linjaa. Yleisin linja oli CC156, johon kuului 61 % kaikista 
penisilliiniresistenteistä kannoista.  Kymmenen prosenttia kannoista kuului 
klonaaliseen linjaan CC271 ja 9 % CC81 -linjaan. Valtaosa penisilliinille resistenteistä 
pneumokokeista oli yhden tai kahden lokuksen variantteja seuraavista PMEN 
klooneista: Spain9V ST156, Taiwan19F ST236, Spain23F ST81, and England14 ST9.  
Vuonna 2002 yleisin makrolidiresistenssimekanismi oli mef geeni (49 %). erm(B) 
geeni löytyi 41 % erytromysiinille resistenteistä pneumokokeista. Kaksoismekanismi 
[mef(E)+erm(B)] havaittiin 5 (2.3 %) kannassa. mef geeneistä yleisin oli mef(E) 
alatyyppi (89 %). Kuudellatoista makrolidiresistentillä pneumokokilla löytyi mutaatio 
joko ribosomissa (domeeni V 23S rRNA) tai ribosomaalisissa proteiineissa (L4, L22).  
Näistä 14 (6.4 %) kannalla ei ollut muuta tunnettua resistenssitekijää. Mutaatioista 
kuusi oli ennen julkaisemattomia. Näistä 4 oli L4 proteiinissa (68E69, 68GQK69, T94I, 
V205G) ja kaksi L22 proteiinissa (R22C, A101P). Vuosina 2002–2006 invasiivisten 
pneumokokkien makrolidiresistenssigeenijakauma oli samankaltainen: mef geeni 
todettiin 56 % tutkituista kannoista ja erm(B) 31 % kannoista. Kaksoismekanismi 
todettiin kahdella kannalla (0.9 %). mef-positiivisista kannoista tutkittiin tarkemmin 60 
kantaa, näistä 72 % oli mef(E) alatyyppiä ja 28 % oli mef(A) alatyyppiä  
Johtopäätökset: Tämän tutkimuksen päähavainto oli pneumokokkien heterogeenisen 
telithromysiiniresistenssin löytyminen. Yhteistä kannoille oli erm(B) 
makrolidiresistenssigeenin löytyminen genomista. Tällaisilla bakteerikannoilla on 
yksittäisiä bakteerisoluja, jotka ovat kykeneviä ilmentämään korkea-asteista 
telitromysiiniresistenssiä laboratoriolosuhteissa. Korkeiden MIC arvojen perusteella 
kuvatunkaltaisella resistenssillä saattaa olla kliinistä merkitystä. Koska CLSI:n 
nestelaimennosmenetelmä ei suosi heterogeenisen telitromysiiniresistenssin 
havaitsemista, erm(B)-positiiviset tai erytromysiinille muuten korkeasti resistentit 
pneumokokit tulisi testata kiekkoherkkyysmenetelmällä. Tutkimuksessa havaittiin 
myös että pneumokokkien makrolidiresistenssi on huolestuttavasti lisääntynyt ja että se 
on erityisen korkea kannoilla, jotka ovat peräisin pienten lasten infektioista. Tästä 
syystä makrolideja ei voi suositella ensisijaislääkityksenä pneumokokki-infektioiden 
hoitoon. Makrolidiresistenssin ohella myös penisilliinille herkkyydeltään 
heikentyneiden kantojen osuus nousi jyrkästi tutkimusajanjaksolla.   
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Abbreviations 
 
A2059 adenine in the position of 2059 of domain V of the 23S rRNA 
(Escherichia coli numbering) 
A2059G adenine replacement by guanine at position 2059 
AOM acute otitis media 
ATP adenosine triphosphate 
AUC area under the concentration curve 
CLSI Clinical Laboratory Standards Institute 
CSF cerebrospinal fluid 
erm  erythromycin ribosomal methylation gene 
ERY erythromycin 
gyr gyrase gene  
I intermediate 
IPD invasive pneumococcal disease 
M macrolide resistance phenotype (resistance to 14- and 15-
membered macrolides) 
mef  macrolide efflux gene 
mega macrolide efflux genetic assembly 
MIC minimum inhibitory concentration 
ML macrolide-lincosamide resistance phenotype 
MLKSB macrolides, lincosamides, ketolides and streptograminB 
MLSB  macrolide-lincosamide-streptogramin B resistance phenotype 
MLST multilocus sequence typing 
msr macrolide streptogramin resistance gene 
par topoisomerase gene 
PBP penicillin binding protein 
PCR polymerase chain reaction 
PEN penicillin 
PFGE pulsed field gel electrophoresis 
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PNSP penicillin non-susceptible (I+R isolates) 
PCV-7 heptavalent pneumococcal conjugate vaccine 
R resistant 
rRNA ribosomal ribonucleic acid 
S susceptible 
ST  sequence type 
SXT trimethoprim-sulfamethoxazole 
TEL telithromycin 
tet tetracycline resistance gene 
TET tetracycline 
Ala, A  alanine 
Arg, R  arginine  
Asn, N  asparagine  
Asp, D  aspartic acid  
Cys, C  cysteine  
Glu, E  glutamic acid  
Gln, Q  glutamine  
Gly, G  glycine  
His, H  histidine  
Ile, I  isoleucine  
Leu, L  leucine  
Lys, K  lysine  
Met, M  methionine  
Phe, F  phenylalanine  
Pro, P  proline  
Ser, S  serine  
Thr, T  threonine  
Trp, W  tryptophan  
Tyr, Y  tyrosine  
Val, V  valine  
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1. Review of the literature  
1.1 Introduction 
Streptococcus pneumoniae or pneumococcus belongs to the genus 
Streptococcus, family Streptoccocceae. Pneumococcus was first 
microscopically observed in 1875 by Klebs in samples from the lungs of 
pneumonia patients. Two researchers, Sternberg in the USA and Pasteur in 
France, independently demonstrated the pathogenicity of the organism in 
1881 by inoculating rabbits with saliva containing pneumococcus. Pasteur 
was the first to successfully cultivate the organism from infected rabbits (19). 
Today, pneumococcus is known as one of the major human pathogens 
worldwide, causing a wide variety of infections. These infections can be 
treated with antimicrobials, but emerging antimicrobial resistance in S. 
pneumoniae is one of the major public health concerns.  
Characteristics of S. pneumoniae 
S. pneumoniae is a Gram-positive coccus that is catalase-negative, non-
motile, non-sporing and produces typical greenish haemolysis 
(alphahaemolysis) in a blood agar base. It requires sera to grow and tends to 
grow in pairs or short chains (212). Pneumococci can be differentiated from 
other alphahaemolytic or viridians streptococci by their susceptibility to 
optochin, bile solubility and capsular reaction to diagnostic pneumococcal 
sera (serotyping) (162). Primary identification of pneumococcus in clinical 
laboratories is frequently based on the typical colony morphology and 
susceptibility to optochin, although some atypical pneumococcal strains can 
show optochin resistance (3, 213), thus making identification sometimes 
difficult.  Apart from serotyping, pneumococci can be further identified, for 
instance, by commercial kits such as Api Rapid Strept, Rapid ID 32 and 
VITEK (bioMerieux, Marcy l'Etoile, France), DNA probe analysis 
(AccuProbe, GEN-PROBE, San-Diego, Ca), PCR (252), sequencing or 
MLST (149).  
The pneumococcus has many virulence factors, of which the polysaccharide 
capsule is one of the most important (185). The capsule protects the bacterial 
cell from phagocytosis and inhibits complement activation (212). Capsular 
polysaccharides are antigenic and they induce a specific antibody response in 
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the host. So far, 91 different capsular serotypes have been detected (161, 
267). Pneumococcus is also capable of switching from one capsule type to 
another (serotype switch) (45, 133, 186). Non-capsulated forms of 
pneumococci also exist (26). Other virulence factors include pneumolysin 
toxin, which is able to lyse eucaryotic cells, pneumococcal surface protein A, 
which has a role in protecting bacteria from attack by host immune defence 
mechanisms (184, 185), and pneumococcal pilus, a hair-like protein 
extending from the surface of the bacterial cell, which enhances the adhesion 
of bacteria to respiratory epithelial cells and stimulates the host immune 
response increasing the pathogenicity of an isolate (22, 156). Additional 
factors that may play a role in virulence include autolysins, signal peptidases 
and numerous surface proteins, but their role is not yet clearly defined (184). 
Epidemiology of pneumococci  
S. pneumoniae is a common inhabitant of the normal nasal microbiota of 
humans. Pneumococci can be isolated from 2 to 65% of healthy people (36, 
129, 160, 217, 226, 259, 301, 328, 336), the carrier rate being higher in 
children than in adults (139, 160). Carriers can harbour different 
pneumococcal strains at the same time (14). Pneumococcus is the major 
pathogen in acute otitis media (AOM) and community-acquired pneumonia 
and a frequent causative organism in invasive bacterial infections such as 
septicaemia and meningitis. In addition, pneumococcus can cause sinusitis, 
cellulitis, endocarditis, fasciitis, abscesses, peritonitis, septic arthritis, and 
pelvic infections (212). Factors associated with an increased risk for invasive 
pneumococcal infection include age (< 2 and > 65 years), male sex, smoking, 
alcoholism, institutionalization, day-care attendance, immune deficiencies, 
and other co-morbidities such as chronic obstructive pulmonary disease, 
diabetes mellitus and cardiovascular disease (269).  
 
Pneumococcal diseases cause significant morbidity and mortality, leading to 
a high burden and costs to health care systems worldwide. In developed 
countries, mortality from invasive pneumococcal infections ranges from <1 
to 30% depending on age and underlying condition (16, 118, 190, 269), but 
can be up to 50% in developing countries (37). In Finland, 500 000 cases of 
AOM have been estimated to occur each year (254), of which pneumococcus 
is an aetiological factor in 26%-60% of the cases (207). Annual incidence 
estimates for S. pneumoniae related community-acquired pneumonia for 
children and the elderly > 60 years of age in Finland are 6.4/1000 (159) and 
8/1000 (197), respectively. According to the National Infectious Disease 
Register, more than 700 cases of invasive pneumococcal disease (IPD) are 
reported annually in Finland, giving an incidence of 14 cases / 100 000 
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inhabitants, the disease burden being the highest in 0- to 4–year-olds (38/100 
000) and those aged 65 years and older (28/100 000) (http://www3.ktl.fi). 
The incidence has remained relatively stable within the past few years.  
Vaccines for preventing pneumococcal infection 
Two types of vaccine against pneumococcal infection are in clinical use: a 
capsular polysaccharide and a conjugate vaccine (277). The pneumococcal 
polysaccharide vaccine (Pneumovax, Sanofi Pasteur, Belgium) contains the 
23 most common capsular polysaccharide antigens: 1, 2, 3, 4, 5, 6B, 7F, 8, 
9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F, 
and induces a B-cell response in the host. The vaccine’s effectiveness in 
preventing IPD is 48-81% in adults with normal immune systems (277). It 
does not reduce the incidence of community-acquired pneumonia, but 
decreases the disease severity, the risk for bacteremia and mortality (277). In 
particular, this vaccine has been shown effective in preventing the 
consequences of pneumonia and mortality among >65 year olds if given 
together with the influenza vaccine (63). The target groups for this vaccine 
are  65–year-olds and those  5-year-olds who are at risk of acquiring 
severe pneumococcal infection (277).   
 
The polysaccharide vaccine does not induce protective immunity in children 
under five years (93). Therefore, a heptavalent conjugate vaccine (PCV-7) 
has been developed (Prevenar; Wyeth Lederle Vaccines S.A., Belgium). It 
contains polysaccharides from seven different capsule types known to cause 
the majority of invasive pneumococcal disease in children: 4, 6B, 9V, 14, 
18C, 19F and 23F. These are linked to a highly immunogenic carrier protein 
(372). The PCV-7 vaccine induces both B and T cell responses as well as 
mucosal immunity. PCV-7 has been proven safe and immunogenic in infants 
and toddlers (313) and very effective in reducing the incidence of IPD and 
other pneumococcal disease in children, as well as in other age groups (279, 
355). Early clinical trials reported a vaccine efficacy of 100-97% against IPD 
caused by vaccine serotypes in vaccine target groups (33).  Later, it was 
illustrated that after introducing the vaccine in the USA, IPD caused by 
vaccine serotypes decreased 94% from 80 / 100 000 in 1998-1999 to 4.6 / 
100 000 in 2003 in children < 5 years, and that overall the reduction in IPD 
incidence in this age group was 75%, from 96.7 to 23.9 / 100 000 (55). In 
addition, the total incidence of IPD decreased by 29% in the whole 
population. The reduction occurred in all age groups, but was most prominent 
in the elderly (55). Early studies also showed that in addition to reducing the 
incidence of IPD, PCV-7 vaccinations reduced AOM cases or the rate of 
visits to physicians due to AOM by 6-9% in infants (104, 127), while larger 
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scale studies showed a 20-40% decline in AOM health care visits on the 
population level (140, 371). Although the results of PCV-7 in reducing the 
burden of pneumococcal diseases have so far been promising, the 
replacement of vaccine serotypes by serotypes not covered by the vaccine 
possesses a threat to this development (88, 314).  
1.2 Antimicrobials used for treating pneumococcal infections 
Macrolides, lincosamides and streptogramines 
Erythromycin was the first macrolide introduced into clinical use in the early 
1950s. Erythromycin is an organic compound produced by the actinomycete 
Streptomyces erythraeus, currently known as Saccharopolyspora erythraea 
(368). Apart from S. pneumoniae, erythromycin is active against Gram-
positive cocci, mycoplasma, Chlamydia, Campylobacter, Bordetella, 
Moraxella, Neisseria and spirochaete species, as well as many anaerobic 
bacteria. Due to the short half life and poor acid stability of erythromycin, 
research was carried out on 14-, 15- and 16-membered macrolides that led to 
the discovery of new macrolide compounds in the late 1980s and 1990s. The 
newer macrolides have better acid stability and more favourable 
pharmacokinetic profiles (48). They also have improved antimicrobial 
activity against mycoplasma and many Gram-negative species (48, 153).  
  
The basic structure of macrolides is a large lactone ring. Erythromycin A has a 
14-membered lactone ring to which L-cladinose and an amino sugar, D-
desoamine, are attached. Other 14-membered macrolides include roxithromycin, 
dirithromycin and clarithromycin, which are derivatives of erythromycin (48). 
Azithromycin is a 15-membered semisynthetic derivative of erythromycin 
belonging to the azalides because it has methylated nitrogen inserted in a lactone 
ring (Figure 1) (21). Spiramycin, rokitamycin, tylosin, josamycin, mideacamycin 
and miocamycin have a 16-membered lactone ring (218).   
 
Macrolides have binding sites in the bacterial ribosome. Erythromycin binds 
to domain V of the 23S rRNA within a tunnel of the peptidyltransferase 
centre, which serves as a channel for a growing peptide chain. The surface of 
the tunnel is formed by domains V and I of 23S rRNA, and by ribosomal 
proteins L22 and L4 (281). The key positions for erythromycin binding are 
A2058 and A2059 (Escherichia coli numbering), A2505, A2062, and U2609 
in domain V. Because hairpin 35 of domain II is also in the vicinity of this 
binding site, A752 may have a role in the binding of the erythromycin. 
Erythromycin blocks the polypeptide exit tunnel and thus prevents the 
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extension of the growing peptide and provokes the premature release of the 
unmature peptide chain. It also prevents ribosomal assembly at an early stage 
of protein synthesis (218).   
 
Lincomycin and clindamycin, a semi-synthetic derivative of the former, 
belong to the lincosamides. Although structurally very different from 
macrolides, lincosamides share a similar mechanism of action with them, as 
also do streptogramins (99). Streptogramins are comprised of two 
components, streptogramin A (dalfopristin, pristinamycin II, or virginiamycin 
M) and B (quinupristin, pristinamycin I, or virginiamycin S).  Alone, these 
components have weak bacteriostatic activity, but their mixture is 
bactericidal and synergistic. Attachment of type A components to a bacterial 
ribosome leads to a conformational change within the peptidyl transferase 
centre that increases type B component affinity 100-fold (154).  
Streptogramin A blocks the substrate sites of the peptidyltransferase centre. 
Type A streptogramins prevent the earliest event of peptide chain elongation, 
whereas type B streptogramins interfere with the formation of the growing 
polypeptide chain similarly to macrolides (339). Figure 1 illustrates the 
structures of some macrolides, clindamycin, quinupristine and telithromycin.  
Ketolides 
Ketolide antimicrobials are a relatively new, recently developed antimicrobial 
group, of which telithromycin (HMR-3647 or RU-66647) and cethromycin 
(ABT-773) are examples (47, 147). Telithromycin was the first ketolide 
introduced into clinical practice at the beginning of the 21st century (363). Its 
antimicrobial spectrum is similar to that of newer macrolides, although it is 
more active (lower MICs) against many bacterial species. Telithromycin is a 
semi-synthetic derivative of erythromycin A composed of a 14-membered 
lactone ring in which the neutral L-cladinose sugar has been replaced by a 
keto group at position C3 (Figure 1). Telithromycin also has a C11/12 alkyl-
aryl extension linked to a carbamate (47). Telithromycin inhibits protein 
synthesis by interacting with domains II and V of 23S rRNA of assembled 
ribosomes, and with part-assembled 50S precursors, causing nucleolytic 
degradation of the precursor particles (1, 47). It has binding sites similar to 
macrolides, but in addition has a binding site at position A752 in hairpin 35 
of domain II (94). Simultaneous interaction both with domain V and domain 
II strengthens binding of the drug to resistant ribosomes, making 
telithromycin a potent drug against macrolide-resistant pneumococci (94). 
Telithromycin concentrates inside neutrophils and macrophages, the drug 
concentration being several times higher in intracellular compared to 
extracellular fluid (270). Telithromycin has inoculum-dependent 
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bacteriostatic and concentration-dependent activity against most respiratory 
pathogens. In addition, a significant post-antibiotic effect, which is 
concentration dependent, has been observed (179, 248), although it is shorter 
against erythromycin-resistant than susceptible pneumococci (248). 
Telithromycin’s main indication is the treatment of community-acquired 
pneumonia. In clinical trials the efficacy of telithromycin has been reported 
to be better than or comparable to other macrolides or betalactams (144).   
Penicillins and cephalosporins 
The core structure of penicillins and other betalactams is a beta-lactam nucleus. 
Beta-lactam antimicrobials inhibit the peptideglycan synthesis of the bacterial 
cell wall by binding irreversively to the active site of penicillin-binding proteins 
(PBPs) leading to osmotic hydrolysis of the bacterial cell (351).  
Betalactam drugs are widely used to treat streptococcal infections. In many 
countries, including Finland, aminopenicillins or penicillin are the first line 
drugs for treating acute otitis media and community-acquired pneumoniae (9, 
17, 18, 125, 157, 256, 272, 285, 286). Cephachlor and cefuroxime are 
examples of second generation cephalosporins, which are recommended as 
second or third line drugs for such infections (71) Ceftriaxone is a third 
generation cephalosporin used for treating severe life-threatening 
pneumococcal infections such as meningitis (178). Cephalosporins share a 
similar mechanism of action with penicillins, but they have a wider 
antimicrobial spectrum (142). First generation cephalosporins are mainly 
active against Gram-positive organisms such as streptococci and 
staphylococci, whilst the spectrum of the later generation cephalosporins is 
more focused on Gram-negative bacteria (23, 142, 284).  
Other antimicrobials 
Fluoroquinolones are synthetic antimicrobials that prevent bacterial DNA 
synthesis by inhibiting the action of DNA gyrase (359). Fluoroquinolones are 
bactericidal and have a wide spectrum of activity. Compared to ciprofloxacin, 
newer fluoroquinolones such as moxifloxacin, levofloxacin and gatifloxacin 
are more active against Gram-positive cocci, including pneumococcus (257, 
304, 311, 337), although the results of one meta-analysis pointed to a similar 
efficacy in clinical situations (241). It has been suggested, however, that the 
use of older fluoroquinolones such as ciprofloxacin should be avoided in 
treating pneumococcal infections because it can favour the selection of clones 
resistant to newer fluoroquinolones (196).  
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Tetracyclines were discovered in the late 1940s. Tetracyclines have wide 
antimicrobial spectrum covering gram-positive and gram-negative bacteria, 
chlamydiae, mycoplasmas, rickettsiae, and protozoan parasites. Tetracycline 
molecule is composed of four linearly fused six-membered hydrocarbon 
rings. Examples of this class antimicrobials are chlortetracycline, 
oxytetracycline, doxycycline and recently developed tigecycline. They inhibit 
protein synthesis in the bacterial cell by binding to the 16S rRNA part of the 
30S subunit of the bacterial ribosome (242).  
 
Sulfonamides were first time used in the early 1930s while the use of 
trimethoprim started in the late 1960s. Soon trimethoprim-sulfonamide 
combination became common because it was considered to act 
synergestically. Both compounds have a wide antimicrobial spectrum 
covering many respiratory pathogens including pneumococcus as well as 
other bacteria, such as Staphylococcus aureus and members of the family 
Enterobactericeae. Trimethoprim-sulfonamides prevent sequential steps in 
bacterial folic acid synthesis (173) 
 
Vancomycin is a tricyclic glycopeptide antimicrobial produced by 
Amycolatopsis orientalis a nocardioform actinomycete. Vancomycin acts by 
inhibiting the synthesis of the cell wall of gram-positive bacteria. Linezolide 
belongs to oxazolidinone class of antimicrobials that are inhibitors of protein 
synthesis. However, unlike many other protein synthesis inhibitors, linezolide 
acts at the initiation phase of protein synthesis by preventing 30S and 50S 
subunits of the ribosome from binding to each other. Linezolide and 
vancomycin are used to treat severe infections caused by Gram-positive 
antimicrobial resistant organisms, including pneumococci. They are often 
considered as reserve drugs for treating life threating infections (57, 347).  
1.3 Antimicrobial resistance mechanisms 
MLKSB antimicrobials 
Macrolide resistance is mediated by two main mechanisms in pneumococcus: 
by target site modification and active drug efflux (56). The most important 
form of target site modification in pneumococci is methylation of ribosomal 
adenine base A2058 by methylases (rRNA adenine N6 methyltransferase), 
leading to a reduced affinity of macrolides to ribosomes. Target site 
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modification can also be achieved via ribosomal mutations. Active drug 
efflux is mediated via efflux pumps and is the prevailing resistance 
mechanism, along with ribosomal methylation in pneumococci (107). 
Enzymes that inactivate macrolides or lincosamides have not been described 
in this bacterial species.  
Methylases 
Ribosomal modification by methylation as a mechanism for macrolide 
resistance was first described in the early 1970s (352). Dozens of different 
types of methylase genes have been detected and sequenced in several 
species such as Streptococci, Staphylococci, E. coli, Enterococci, Clostridium 
perfringens, Lactobacillus reuteri, Arthrobacter luteus, Corynebacterium 
difteriae, Bacteroides fragilis, Bacillus and Streptomyces. Methylase 
enzymes catalyse either mono- or dimethylation of a particular adenine 
residue in the 23 rRNA (352). In S. pneumoniae the prevailing methylase 
gene is erm(B), which was originally designated as erm(AM) and was 
initially found from a plasmid pAM77 of Streptococcus sanguis (218, 352). 
The ErmB enzyme predominantly catalyses the dimethylation of the 
ribosomal adenine base at position 2058 of domain V in 23S rRNA, leading 
to a reduced affinity of erythromycin for ribosomes. Dimethylation of this 
site confers cross resistance to 14-, 15- and 16-membered macrolides as well 
as to clindamycin and streptogramin B. Consequently, this type of resistance 
is termed MLSB resistance (353). Due to the synergistic effect of 
streptogramin A and B, a combination of streptogramins is effective against 
isolates showing the MLSB phenotype, although MICs may be slightly 
elevated (346). The other methylase gene in pneumococcus, although rarely 
present, is erm(A), which was originally designated as erm(TR) (309). 
erm(TR) was first described by Helena Seppälä and her co-workers, who 
observed it in Streptococcus pyogenes (309). Because erm(TR) is closely 
related to erm(A) of Staphylococcus aureus, it was later recommended that 
the name erm(A) should be used instead of erm(TR) so as to avoid 
complexity in the nomenclature (294). erm(A) and erm(B) share only 58% 
similarity at the nucleotide level (309).    
 
Resistance to MLSB antimicrobials may be constitutive or inducible in 
isolates harbouring the erm gene (353). Phenotypes of inducible strains show 
resistance to 14-, 15- and 16-membered macrolides, but susceptibility to 
clindamycin and/or streptogramin B is variable (56) After the incubation of 
such isolates in a low concentration of 14- or 15-membered macrolides, an 
elevation of MICs of clindamycin and streptogramin-B can be observed 
(353). In disk diffusion susceptibility testing, the induction is manifested by 
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D-shape blunting of the growth inhibition zone around the lincosamide or 
streptogramin disk adjacent to the 14- or 15-membered macrolide disk (353). 
The inducibility of the erm(B) gene is related to the leader sequence the 
preceding the methylase gene. Mutations or deletions in the leader peptide 
can convert inducible resistance to the constitutive form (353). Bacterial 
phenotypes with constitutive MLSB resistance are highly resistant to these 
antimicrobials (218).  
 
Pneumococcal erm genes locate in numerous transposons, which spread 
either by transformation or conjugation. Transposons have inverted repeat 
(IRs) sequences at each end and carry genetic codes for transposases, 
enzymes that allow transposons to be cut from DNA and inserted at different 
positions in the genome. Insertion sequences (IS) are the simplest forms of 
transposons. Composite transposons contain the insertion elements at either 
end, but can contain other genes in the middle. These types of transposons 
are usually very large because they can contain derivatives of several smaller 
transposons. All erm(B)-carrying elements are derivatives of the tetracycline 
tet(M)-carrying Tn916 transposon, which was originally detected in 
Enterococcus faecalis (128). Tetracycline determinants carried in the same 
transposons together with erm(B) can be silent (67). An example of a 
composite transposon in S. pneumoniae is Tn3872, in which erm(B) carrying 
transposon Tn917 is integrated into Tn916 (232). Other erm(B)-containing 
transposons in pneumococci include Tn1545, Tn6003, Tn6002 (67). Tn1545 
was the first transposon described in pneumococcus. It is a conjugative 
transposon containing erm(B), tet(M) and aphA-3 (kanamycin resistance) 
resistance genes with a size of 25.3 kb (72, 73). Tn6002 (size 20.9 kb) 
evolved from the insertion of an erm(B)-containing DNA strand into Tn916 
(68). Tn6003 is a 25.1 kb composite transposon carrying the same resistace 
genes as Tn1545 (68), but besides the kanamysin resistance determinant an 
additional erm(B) gene without a stop codon can exist (68). In pneumococci 
carrying erm(B) and mef(E), a mef-containing mega element is inserted in a 
transposon similar to Tn2009, forming a new 226.3 kb composite transposon 
Tn2010 (85).  
Active efflux of the drug 
Until 1993, before Helena Seppälä and colleagues described a novel M-
phenotype in Streptococcus pyogenes (308), it was thought that macrolide 
resistance in streptococci was exclusively mediated by erm(B) (325). Isolates 
of the M phenotype were observed to be resistant to 14- and 15-membered 
macrolides, but not to 16-membered macrolides, lincosamides or 
streptogramin B (308). Later, this phenotype was also described in S. 
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pneumoniae (325). In 1996 it was discovered that resistance in M phenotype 
pneumococci and streptococci was due to active drug efflux, since 
erythromycin uptake by the bacterial cell was increased in the presence of 
carbonylcyanide m-chlorophenylhydrazone (CCCP) or arsenate, the agents 
that disrupt proton motive force in strains with the M-phenotype (327). 
Finally, molecular cloning and functional analysis proved that the gene 
responsible for coding the efflux pump mechanism in Streptococcus 
pyogenes was mef(A) (GenBank accession number U70055) (64). Soon, Tait-
Kamradt and co-workers (1997) described the presence of a similar gene, 
mef(E) (GenBank accession number U83667), in S. pneumoniae (331). mef 
genes are homologous to transporters using proton motive force, unlike msrA 
and msrB in staphylococci. Effux pumps coded by mef genes belong to the 
major facilitator superfamily (MFS), in which the extrusion of a drug is 
coupled with ion exchange (325).  Both subtypes of mef genes, mef(A) and 
mef(E), have been detected in pneumococci (77, 86, 303). Sequencing 
analysis has revealed that these two genes are closely related, sharing 90% 
identity at the DNA level and 88% similarity at the protein level (331). 
Consequently, it was first suggested that they should be reported as a single 
gene, mef(A), to avoid conflicting interpretations and complexity in 
nomenclature (294). However, regardless of the high degree of identity 
between mef(A) and mef(E), numerous differences were later discovered. 
mef(A) and mef(E) were found to be carried by different genetic elements 
(77, 86). mef(A) of pneumococcus is part of a chromosomal element, a 
defective transposon designated to Tn1207.1 (303), while mef(E) is carried by 
a chromosomal insertion element, designated the macrolide efflux genetic 
assembly or mega (86). The mega element has at least five insertion sites in 
the pneumococcal genome (132). Erythromycin MICs of isolates which carry 
the mef(A) element were shown to be higher compared to isolates carrying 
mef(E) (8). Penicillin non-susceptibility is commonly found together with 
mef(E), but is not as frequent in the presence of mef(A) (15, 69, 86). 
Moreover, mef(A)-carrying isolates are usually clonally related, whilst mef(E) 
isolates have a more heterogenetic pattern (15, 69, 86). Because of these 
differences, it was suggested that the genes should be discriminated (86). 
Recently, one new variant of mef gene, designated as mef(I), was described in 
two pneumococcal isolates by Cochetti and co-workers (69). The new variant 
was not carried by a mega element. The amino acid sequence coded by mef(I) 
showed 96.5% similarity with that of mef(E) and 94.3% with the amino acid 
sequence coded by mef(A) (69). Later, it was observed that mef(I) is carried 
by a novel composite genetic element, designated as the 5216IQ complex. 
The size of this element is around 30 kb and it is composed of parts of the 
transposons Tn5252 and Tn916 and a new element designated as IQ (240).  
 
1. Review of the literature
THL — Research 9 23 Antimicrobial resistance in Streptococcus  
  pneumoniae in Finland with special  
 reference to macrolides and telithromycin 
An additional efflux mechanism, designated as msr(D) (8, 47) or mel (21) 
[hereafter msr(D)], has been found in all three mef carrying genetic elements 
in pneumococcus (77, 240). msr(D) is a homologue of the msr(A) 
determinant found in staphylococci (77), which codes an ATP-binding 
cassette (ABC) transporter that utilizes the energy derived from ATP 
hydrolysis to efflux drugs (325). mef and msr(D) genes are co-transcribed in 
pneumococci. The msr(D) gene has also been shown to be capable of 
conferring resistance to 14- and 15-membered macrolides without the mef 
determinant in pneumococcus (77). The expression of the mef-msr(D) efflux 
mechanism has been illustrated to be inducible by a low concentration of 14- 
and 15-membered macrolides, elevating their MICs, but does not affect the 
MICs of 16-membered macrolides, clindamycin or streptogramin B (6).   
Ribosomal mutations 
Macrolide-resistant pneumococci that do not harbour common resistance 
genes usually have ribosomal mutations that appear to cluster in the 
peptidyltransferase region in domains V and II of 23S rRNA, or in 50S 
ribosomal protein coding genes L4 or L22. Mutations in these areas prevent 
the antimicrobial binding to its target site (218, 352). Phenotypes of mutated 
strains are variable, depending on the location of the mutation(s), the number 
of mutated alleles and probably the level of expression of the gene (108, 332, 
333). Azithromycin is considered to be one of the most potent macrolides for 
selecting mutants (52).  Laboratory experiments show that after serial 
passage of pneumococcal strains in azithromycin, mutations can be observed 
at positions A2058G, A2059G, C2611A and C2611G of the peptidyl 
transferase region at domain V of 23S rRNA. In addition, amino acid changes 
were detected in a highly conserved 63KPWRQKGTGRAR74 region (333). 
These mutations have also been observed in clinical isolates. The most 
frequently reported ribosomal mutation in clinical isolates seems to be 
A2059G (92, 108, 290), while A2058G mutation is less frequent, although it 
is rather common in Streptococcus pyogenes (40, 116, 183). Table 1 
summarises the different types of ribosomal mutations associated with 
macrolide resistance in clinical and laboratory pneumococcal strains.  
Mechanisms of telithromycin resistance 
Telithromycin has been reported to be active against erythromycin-resistant 
strains of S. pneumoniae, regardless of the resistance mechanism (182, 214, 
215, 245, 354). Pneumococcal strains that harbour erm or mef genes have 
higher MICs for telithromycin than wild type isolates (0.5 vs. 0.015 mg/L), 
but their telithromycin MIC does not usually exceed the susceptibility 
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breakpoints set by CLSI (113, 182, 215, 245, 354). However, telithromycin 
resistance has been described in isolates in which there are mutations in the 
erm(B) leader sequence (166). In some cases, the telithromycin resistance 
mechanism is unclear but is somehow associated with the presence of erm(B) 
(349). In mef-carrying isolates, telithromycin MIC elevation may be linked to 
the msr(D) determinant instead of mef, since in laboratory experiments 
msr(D) transformants were observed to have higher telithromycin MICs than 
transformants with only the mef gene (77). Telithromycin has also been 
shown to be active against many pneumococcal strains that have a ribosomal 
mutation (108). However, there are some exceptions. In one report a S. 
pneumoniae isolate with an 18-base-pair insertion in the gene coding the L4 
protein had a telithromycin MIC of 3.12 mg/L (332). Pihlajamaki and co-
workers described a 12 base pair amino-acid insertion (Val-Arg-Pro-Arg) 
after position 277 in the gene encoding L22. The telithromycin MIC of this 
strain was 2 mg/L, but MICs to macrolides were relatively low (273). 
Mutations at the position of A752 in hairpin 35 of domain II have also been 
associated with telithromycin MIC elevation (166).  
Other antimicrobials 
Resistance against betalactams in pneumococci is mediated via changes in 
the genes encoding penicillin-binding proteins PBP1a, PBP2x, and PBP2b 
(138) and cell wall muropeptide branching protein MurM  (126), leading to a 
reduced affinity of PBPs for the betalactam drugs. High level resistance is 
usually acquired by multiple mutations in the genes encoding PBPs. These 
genes are also called mosaic genes, referring to the long adjoining nucleotide 
sequences within PBP genes (59, 155). The acquisition of mosaic genes may 
occur via transformation from the same or closely related bacterial species 
(70, 146, 155). Pneumococcal isolates with a reduced susceptibility or 
resistance to penicillin often also have a diminished susceptibility to other 
betalactam antimicrobials, including newer cephalosporins (38, 122), 
although not necessarily to the extent that they would exceed non-
susceptibility breakpoints. However, pneumococcal isolates with full 
resistance to penicillin are often also non-susceptible to second or third 
generation cephalosporins (122). 
Resistance to fluoroquinolones is encoded by mutations in either parC or 
parE genes of topoisomerase IV or in gyrA or gyrB genes of DNA gyrase. 
These mutations can occur in combination or separately (2, 152, 263, 264, 
276, 278, 370). They commonly appear in a stepwise fashion, leading first to 
a slightly decreased susceptibility to fluoroquinolones. Additional mutation 
in the other target gene leads to full resistance. Enhanced efflux of certain 
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fluoroquinolones, mediated by membrane-associated protein PmrA, has also 
been documented as a fluoroquinolone resistance mechanism in 
pneumococcus (42). It has been suggested that apart from spontaneous 
mutations, the horisontal transfer of genetic material might play role in the 
developement of fluoroquinolone resistance (175).  
 
Tetracycline resistance in pneumococci is mediated via the tet(M) or tet(O) 
genes, which encode ribosomal protection proteins leading to a displacement 
of tetracycline from its binding site (357). Tetracycline resistance is 
frequently linked with erythromycin resistance because tetracycline 
determinants are carried by the same transposons as erm(B) (49, 67, 310). 
Therefore, high tetracycline resistance rates are usually reported by the 
countries in which high macrolide resistance percentages, due to erm(B), are 
observed.  
 
Resistance to trimethoprim-sulfonamides is due to mutations in dihydrofolate 
reductase and dihydropteroate synthase, enzymes responsible for folic acid 
synthesis (173, 356) while point mutations in the genes coding 23S rRNA, 
such as G2576T, has been reported to mediate resistance to linezolid (235).  
1.4 Occurrence of antimicrobial resistance  
Susceptibility testing and breakpoints  
Several methods have been developed for testing antimicrobial susceptibility 
in vitro.  Roughly, these can be divided into dilution susceptibility tests and 
disk diffusion tests. The former tests measure the minimum inhibitory 
concentration (MIC) of an antimicrobial in mg/L or μg/ml that prevents 
bacterial growth, while the latter tests provide qualitative results usually 
classifying bacteria into three susceptibility categories: resistant (R), 
intermediate (I) or susceptible (S) (212). To interpret susceptibility testing 
results, breakpoints for the separate susceptibility categories need to be 
determined. The breakpoints should be based on the distribution of the (wild 
type) bacterial population, pharmacokinetic and dynamic parameters of the 
tested drug in question as well as clinical trials. Many existing breakpoints 
have been set in relation to achievable drug serum concentrations, but 
recently the importance of pharmacodynamic parameters in setting up 
breakpoints has also been addressed (7).  
Although the primary aim of antimicrobial susceptibility testing is to provide 
information for a clinician to choose the optimal antimicrobial treatment for a 
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patient, its results can be used to follow changes in the antimicrobial 
resistance of certain bacterial populations over time (75). Many 
organizations, such as the British Society for Antimicrobial Chemotherapy, 
the Swedish reference group for antimicrobials, the Clinical Laboratory 
Standards Institute (CLSI, formerly NCCLS) in the USA and the European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) in the EU 
have worked to standardise and harmonise antimicrobial susceptibility testing 
and breakpoints (198). Due to the parallel work of many organisations, there 
is considerable variation in the breakpoints that have been set, making 
comparison of the data from different sources and studies challenging, 
although CLSI breakpoints have so far been widely used in the literature. The 
European breakpoints usually tend to be more conservative compared to 
CLSI breakpoints. For example, telithromycin breakpoints for the susceptible 
and resistant categories are, respectively,  1 and  4 mg/L according to the 
CLSI (66) and  0.25 and  1 mg/L according to EUCAST 
(http://www.srga.org/eucastwt/MICTAB/MICmacrolides.html). In addition, 
re-setting of breakpoints may affect greatly to susceptibility categorisation of 
the bacterium. One such example is from USA where the proportion of 
penicillin non-susceptible pneumococci declinded from 25% to 7%  after data 
from 2006-2007 were analysed by using new penicillin breakpoints for non-
meningeal invasive pneumococci that were published by CLSI in 2008 (10).  
Macrolide and ketolide resistance 
 
Dixon was the first to alert the scientific community to the development of 
erythromycin resistance in 1967, although the first anecdotal report on 
erythromycin resistance in pneumococcus occurred as early as in 1964, 
twelve years after the drug was launched for commercial use (211). In the 
1980s the emergence of erythromycin resistance in pneumococci was 
evident: 0.3-6.3% of investigated pneumococci in the USA and 1.7-7.9% in 
Spain were reported to be resistant to erythromycin, while in France and in 
Belgium the respective proportion was already over 10% (211). Today, 
pneumococcal resistance to macrolides is a worldwide problem, although the 
prevalence of resistance varies greatly between countries, from 3% to 90% 
(89, 120, 158, 176, 187, 220, 229, 282, 293, 307, 317, 320, 336, 365). The 
highest prevalence of erythromycin resistance is in the Far East (~80%), 
followed by South Africa (~54%), southern Europe (~37%), northern Europe 
(~18%) and Latin America (~15%) (120).  In the USA, erythromycin 
resistance in 2000-2004 was estimated at ~30% (187). Europe’s hot spots of 
macrolide resistance are southern Europe and the Mediterranean region 
(prevalence  44%) (293). Countries with a low prevalence of macrolide 
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resistance (<11%) include Austria, the Czech Republic, Estonia, Norway, 
Portugal, Sweden, Russia, and the Netherlands (5, 107, 319). In Finland the 
prevalence was < 7% in 1999-2000 (273). Figure 2 presents the level of 
macrolide resistance among invasive pneumococci in European countries 
participating in the European Antimicrobial Resistance Surveillance System 
(EARSS) in 2005 (http://www.rivm.nl/earss). 
 
So far, the telithromycin susceptibility of pneumococci has remained very 
good. At the time when telithromycin was undergoing clinical trials a 
worldwide longitudinal surveillance project to monitor the telithromycin 
susceptibility of respiratory pathogens was also introduced. This study was 
named PROTEKT (Prospective Resistant Organism Tracking and 
Epidemiology for Ketolide Telithromycin). Under the framework of this 
project, thousands of pneumococcal isolates have been collected since 1999 
at regular intervals from dozens of countries all over the world. Susceptibility 
testing is performed in one laboratory with a standard method, which makes 
the estimation of trends reliable. So far it seems that the proportion of 
telithromycin non-susceptible pneumococci worldvide has remained at  
0.3% and no increasing trend has been detected (120). In other publications 
the prevalence of telithromycin non-susceptibility has ranged from 0.02% to 
3.6%, depending on the investigated pneumococcal population, breakpoints 
and methods used (24, 28, 40, 81, 109, 113, 169, 170, 182, 214, 215, 245, 
342, 354). However, despite the satisfactory telithromycin resistance 
situation, several anecdotal reports have been published to date on clinical 
pneumococcal isolates showing a high level of resistance to telithromycin 
(106, 135, 165, 166, 289, 360, 362).  
Penicillin resistance 
Resistance to penicillin in a laboratory mutant pneumococcus was reported as 
early as the 1940’s (211), but the first clinical pneumococci with elevated 
MICs to penicillin (MIC 0.1-0.2 mg/L) can be found in the report by Kislak 
and co-workers in Boston, USA, in 1965 (209). Two years later, a penicillin 
non-susceptible pneumococcus was isolated from a 25-year-old patient in 
Australia with a previous history of multiple antimicrobial treatments and 
hypogammaglobulinemia (151). This was followed by the emergence of 
penicillin-resistant isolates in New Guinea (211). Thereafter, penicillin 
resistance in pneumococci rapidly increased in many parts of the world. In 
1977 there was an outbreak in South Africa caused by penicillin-resistant 
pneumococci (MIC 4-8 mg/L) that also were resistant to tetracycline, 
macrolides and chloramphenicol (56). In 1974-1984, already more than 10% 
of clinical pneumococcal isolates were penicillin non-susceptible in New 
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Guinea, Israel, Poland, South Africa, Spain, and in many states of the US 
(11), but pneumococci isolated from healthy carriers had even higher 
penicillin non-susceptibility rates of up to 36% (211). To date, the global 
penicillin non-susceptibility level has reached 36-37%, while the proportion 
of fully resistant strains is 23% (120). The highest penicillin non-
susceptibility rates are in South Africa and the Far East (> 60-70%), followed 
by southern Europe (35-40%), Latin and North America (30-35%), and 
Australia (20-25%). The lowest penicillin non-susceptibility rates have been 
reported in northern Europe (10-15%) (120). Figures 3 and 4 present the 
penicillin non-susceptibility and penicillin resistance percentages of invasive 
pneumococci in European countries participating in EARSS in 2005 
(http://www.rivm.nl/earss).  
Fluoroquinolones and other antimicrobials 
Fluoroquinolone resistance is still quite rare ( 2%) among pneumococci, 
although it has been observed to have increased within the past ten years (2, 
58, 87, 91, 287). For instance, in Canada there were no fluoroquinolone-
resistant pneumococci in 1993, but in 1997 their proportion was 1.7%. At the 
same time, fluoroquinolone prescriptions increased from 0.8 to 5.5/100 
persons/year (58). In North America the proportion of ciprofloxacin-resistant 
pneumococci increased from 1.7 to 2.0% and levofloxacin-resistant 
pneumococci from 0.2% to 0.9% during 1997 to 1999 (194), while in 2001-
2002 levofloxacin resistance had reached 1.1-1.3% in the USA (199). 
According to one international study that included seven countries 
worldwide, 1.3% (range 0-3%) of pneumococci were resistant to levofloxacin 
(246). A similar result was presented following another study (120). The 
highest fluoroquinolone resistance percentages have been reported in Italy 
(3%) (246), Hong Kong  (3.8%) (167) and South Korea (3.8%) (312). 
Gatifloxacin resistance percentages are usually close to that of levofloxacin, 
but moxifloxacin resistance is usually lower due to its higher potency against 
pneumococcus (304). However, it must be noted that a pneumococcus 
showing diminished susceptibility to ciprofloxacin often has a mutation in a 
fluoroquinolone resistance target gene and is therefore also prone to 
developing resistance to newer quinolones.   
 
Tetracycline resistance began to emerge as early as in the 1960s. By 1963-
1964 in Australia, 25% of pneumococci isolated in hospitals were 
tetracycline resistant. Three years later in England, 18% of hospital isolates 
were reported to be tetracycline resistant, while the respective proportion in 
outpatients was 12% (211). Tetracycline resistance in the USA was around 
15% in 2000-2004 (187) and in Europe ~ 20% in 2004-2005 (293). In Russia, 
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more than half of pneumococci isolated from carriers under five years old 
were observed to be resistant to tetracycline in 2001-2001, even though 
macrolide resistance was under 7% (323). This result may indicate 
differences in antimicrobial usage and therefore in selection pressure between 
the countries, but also differences in study designs or the origins of 
pneumococcal isolates.  
 
Resistance to trimethoprim sulphonamide compounds was first detected in 
1972 (211). It is now clear that the benefits of these drugs are being eroded 
by emerging resistance in pneumococci (173); the resistance to this 
antimicrobial class was 26.7% in Europe in 2004-2005 (293) and 24% in the 
USA (187). In Russia, the respective proportion was as high as 65% among 
children under 5 years old in day-care centres and orphanages (323). 
 
Resistance to linezolide is extremely rare in pneumococci (347, 361). 
Resistance to vancomycin has not yet been observed in this bacterial species, 
although vancomycin-tolerant pneumococci have been described (163, 231, 
255, 295, 324). The affinity of the drug to its binding site does not change 
and the MIC does not increase in such strains (163), but these isolates are 
able to escape lysis and killing by vancomycin, although the underlying 
mechanism is not yet clear (163, 324). Increased mortality has been noticed 
in meningitis patients if the causative organism is vancomycin-tolerant 
pneumococcus (295). 
 
1.5   Clinical relevance of antimicrobial resistance  
The clinical significance of antimicrobial resistance in pneumococci in vitro 
has been under continuous debate (119). Numerous reports have been 
published on this issue (30, 76, 96, 130, 163, 177, 205, 210, 224, 225, 271, 
272, 299). Some studies have failed to find an association between 
antimicrobial resistance and the investigated outcome (i.e mortality or 
treatment failure) (321), especially when other risk factors and confounders 
have been taken into account (105, 168, 239, 262), while several others have 
documented such an association (222, 223, 253, 305, 341). Furthermore, 
there are dozens of case reports or series on pneumococcal infections in 
which treatment has failed due to antimicrobial resistance (41, 43, 54, 78, 82, 
97, 98, 100, 101, 141, 174, 189, 203, 204, 206, 231, 260, 298, 318). The 
majority of these are macrolide or fluoroquinolone related, while reports of 
betalactam treatment failures are less frequent. On the basis of this evidence, 
it is clear that antimicrobial resistance has clinical significance. It is affecting 
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several parameters of morbidity by increasing the risk of breakthrough 
infections, the duration of illness and the costs of treatment. However, its 
effect on mortality is controversial (31, 239, 272, 364) or has been difficult to 
show due to factors such as the low statistical power in studies with small 
numbers of enrolled patients, difficulties in controlling for confounding 
factors (e.g co-morbidities, immune status, underlying diseases) or bias (e.g. 
in the selection of study subjects), retrospective study designs, and ethical 
reasons (299). 
 
It has been suggested that low-level resistance, particularly in the case of 
betalactams and macrolides, has no clinical relevance (30, 31). Current 
evidence actually supports this claim for low-level betalactam resistance: 
infections caused by pneumococcal isolates showing intermediate 
susceptibility are treatable with betalactams as long as a higher dose and a 
more frequent dosing interval are used (18) in order to lengthen the time the 
drug concentration is above the MIC. However, proper pharmacodynamic 
parameters are difficult to achieve with tapering of the dose if a bacterial 
strain is fully resistant to penicillin (122). Studies show higher rates of 
mortality or suppurative complications in such infections (118, 239, 341) and 
they should therefore be treated with other agents (18) or combination 
therapy (247).  
 
Regarding low-level macrolide resistance, such pneumococci usually have a 
relatively low macrolide MIC (2-16 mg/L), a concentration that should easily 
be achievable by macrolides at the infection site, and are therefore considered 
by some investigators to be treatable with macrolides (30). However, there is 
now increasing evidence that low-level macrolide resistance does have a 
clinical impact (174, 222, 305). For example, Lonks and co-workers 
described an increased risk of breakthrough bacteremia during macrolide 
therapy in patients with macrolide-resistant pneumococcus (222). They also 
documented breakthrough bacteremia in patients whose infection was caused 
by pneumococci showing a low-level resistant M phenoype (222). Another 
publication documented a case series of 122 patients with macrolide 
treatment failure (174). The majority of failures, including deaths, were in 
infections caused by pneumococci showing low-level macrolide resistance 
(174). A recent study demonstrated that treatment failures with macrolides 
are preceded by a low area under the inhibitory concentration-time curve 
(AUIC = AUC24/MIC  10 for azithromycin,  31 for clarithromycin, and  
53 erythromycin) and that patient factors such as co-morbidities were not in a 
key role in predicting the outcome (305). An earlier study revealed that 
pneumococci with azithormycin MICs > 2 mg/L are not eradicated by 
clinically achievable free drug concentrations in the blood or lungs, 
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regardless of the resistance genotype (305, 367). In addition, MICs of mef-
carrying pneumococci have been documented invading to the right over time 
(107), increasing the clinical significance of this genotype.   
1.6 Molecular typing methods to examine the epidemiology of 
drug resistant pneumococci 
The epidemiological investigation of pneumococci has become necessary 
along with the rapid emergence of antimicrobial resistance. Conventional 
typing methods based on phenotypical characters, such as serotyping or 
antimicrobial profile (antibiogram) determination, are not sufficient to 
investigate the relatedness of different isolates. Therefore, several molecular 
typing methods, such as pulsed field gel electrophoresis (PFGE) and 
multilocus sequence typing (MLST) have been developed and successfully 
used (103, 164, 234). 
 
In PFGE the bacterial genome is cut with a restriction enzyme, usually into 
10-30 fragments ranging from 10 to 800 kb. These fragments are then 
separated on an agarose gel using an electric current that pulses between 
three sets of electrodes, allowing DNA pieces to migrate through the gel 
PFGE has a high discriminatory power and is reproducible, but it is laborious 
and time consuming. In addition, interlaboratory comparison of the results 
can be challenging. Nevertheless, PFGE is widely used for investigating the 
genetic relatedness of several bacterial species. It is has been shown to be an 
effective tool for genotyping, especially if isolates have been collected within 
a relatively short period of time from a restricted geographical region, such as 
from suspected outbreaks (338). 
        
Multilocus sequence typing (MLST), which was introduced in 1998, is 
currently considered as the gold standard for molecular typing of 
pneumococcal strains. The method is based on the sequencing of seven 
housekeeping genes or fragments of them, which allows the identification of 
pneumococcal clones and clonal complexes and also provides information on 
the genetic relatedness of isolates that differ at less than four of the seven loci 
(103)  Apart from clonality studies, MLST can also be used to define 
pneumococcus species (149). The results of MLST are much easier to 
compare between the laboratories than PFGE results. On the other hand, in 
outbreak settings, PFGE has better discriminatory power compared to MLST.  
 
The Pneumococcal Molecular Epidemiology Network (PMEN) was 
established in 1997 with the aim of characterizing, standardizing, naming and 
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classifying antimicrobial agent-resistant pneumococcal clones (234). In order 
to include a pneumococcal clone in the PMEN it has to fulfil the following 
criteria: 1) the clone must have a wide geographical distribution in a country 
or internationally; 2) the clone should have been present within a country for 
several years; 3) the clone should be resistant to one or more widely used 
antimicrobials; 4) data on the clone need to be published or in press prior to 
ratification of the network; and 5) a representative isolate should be provided 
in order to confirm that it differs from previously accepted PMEN clones. In 
addition the source must grant that the strain will be stored in the ATCC 
(American Type Culture Collection). By 2001, the PMEN described the 
nomenclature and characters of 16 drug-resistant pneumococcal clones 
concerning the worldwide spread of antimicrobial resistance. Examples of 
widely spread global clones include Spain23F – 1 and Taiwan19F-14 clones. 
The former was first described in Spain in the late 1980s and the latter in 
Taiwan in the 1990s. To date, these clones have spread to many European 
countries, the USA, South Africa, South America and the Far East (McGee et 
al., 2001). By August 2008, 26 PMEN clones had been described. Their 
nomenclature, MLST data and genetic relatedness are provided on the Multi 
Locus Sequence Typing Internet site (http://spneumoniae.mlst.net/pmen). 
1. Review of the literature
THL — Research 9 33 Antimicrobial resistance in Streptococcus  
  pneumoniae in Finland with special  
 reference to macrolides and telithromycin 
 
 
 
 
Figure 1. Chemical structure of A) erythromycin,14-membered macrolide:  
B) azithromycin, azalide, 15-membered ;  C) spiramycin, 16-membered 
macrolide; D) clindamycin, lincosamide; E) quinupristin, streptogramin B;  
and F) telithromycin, ketolide. 
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Table 1. Overview of ribosomal mutations in clinical (C) and laboratory-derived (L) pneumococci and their MICs to 
erythromycin (ERY), clindamycin (CLI), spiramycin (SPI), quinupristin (QUI) and telithromycin (TEL) reported in macrolide-
resistant pneumococci.  
Mutation Target** ERY CLI SPI QUI TEL Isolate type** References 
A2059C Domain V 512 0.5-1 512 16-32 0.063-0.125 C (275) 
 
A2059G 
 
Domain V 
 
2-512 
 
0.12-2 
 
>100-512 
 
1.56->128 
 
0.01-0.063 
 
C, L (ROX, 
AZM)
 
(52, 92, 108, 
275, 332, 333)
 
A2058G 
 
 
Domain V 
 
 
1->100 
 
 
0.12-16 
 
 
6.25 
 
 
16->128 
 
 
0.01-0.5 
 
 
C, L(AZM) 
 
 
(52, 92, 108, 
333)  
 
A2058U 
 
Domain V 
 
>32 
 
1 
 
 
 
 
 
0.25-1 
 
L(CLA) 
 
(52) 
 
C2611T 
 
Domain V 
 
 0.12 
 
0.5-1 
 
 
  
 
C 
 
(92) 
 
C2611G 
 
 
Domain V  
 
 
0.5->512 
 
 
0.06-1 
 
 
0.78-16 
 
 
64-128 
 
 
0.015-0.5 
 
 
C  L(AZM) 
 
 
(108, 275, 
333) 
 
C2610U 
 
Domain V 
 
0.06 
 
0.5  
 
 
 
0.008 
 
L (CLA) 
 
(52) 
 
C2611U 
 
Domain V  
 
0.06-0.125 
 
0.5-2 
 
 
 
 
 
0.008-0.08 
 
L(AZM, CLI) 
 
(52) 
 
C2611A 
 
Domain V 
 
0.78 - >64 
 
0.20-0.25 
 
1.56 
 
50 
 
0.01-0.06 
 
C, L (AZM) 
 
(108, 333) 
A2059G+  
G2057A Domain V >64 8 ***  0.25 C 
 
(108) 
A2059G+ 
A2059C 
 
Domain V 64 1 ***  0.25 C (108) 
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A2059C+ 
L4 G71R 
Domain V, 
L4 
>64 32 ***  0.25 C (108) 
A2058U+ 
L4 I78V 
 
Domain V 
23, L4 
 
>64 
 
 
0.25-0.5 
 
 
*** 
 
 
 
 
 
0.5 
 
 
C 
 
 
(108) 
 
A2059G+  
L22 G95D 
 
Domain V, 
L22 
 
64->64 
 
 
1-2 
 
 
*** 
 
 
 
 
 
0.6 
 
 
C 
 
 
(108) 
 
A752 
Deletion 
 
Domain II 
 
 
>32 
 
 
1 
 
 
 
 
 
 
4 
 
 
L (CLA) 
 
 
(52) 
 
69GTG71to 
69TPS71 
 
L4 
 
 
>128->512 
 
 
<-0.12-0.25
 
 
64 
 
 
16 
 
 
0.25 
 
 
C 
 
 
(92, 275, 332) 
 
G69C 
mutation 
 
L4 
 
 
0.05 
 
 
0.20 
 
 
 
 
 
3.12 
 
 
0.006 
 
 
L (AZM) 
 
 
(333) 
 
67SQ68 
insertion  
L4 
 
0.20 
 
0.05 
 
 
3.12 
 
0.01 
 
L (AZM) 
 
(333) 
 
71REKGTG7
2 insertion L4 6.25 0.05  25 3.12 C (332) 
65WR66 
deletion**** L4 1 0.06  8 0.008 C 
 
(361) 
68KG69 
deletion**** L4 2 0.06  8 0.008 C 
 
(361) 
K68S 
mutation+ 
69GTGR72 
deletion 
 
L4 
 
 
64 
 
 
1 
 
 
*** 
 
 
 
 
0.12 
 
 
C 
 
 
(108) 
 
 
68KE69 to 
68KEG69inse
rtion 
L4 64 0.25 ***  0.015 C (108) 
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64PWRQ67 
to 64P__Q67  
deletion 
L4 
 
 
2 
 
 
0.25 
 
 
***** 
 
 
 
 
0.03 
 
 
C 
 
 
(108) 
 
69GT70 to 
 69VP70 
change
L4 
 
>64 
 
0.25 
 
*** 
 
 
0.03-0.06 
 
C 
 
(108) 
 
69GTG71 to 
69TPS71 + 
V88I 
 
L4 
 
>64 
 
0.5-1 
 
*** 
 
 
0.12 
 
C 
 
(108) 
108RTAHIT110  
tandem 
duplication
 
L22 
 
1-32 
 
 
 
0.03-0.5 
 
 
 
 
1 
 
C 
 
(92, 108) 
 
G95D 
mutation 
L22 
 
0.25-1 
 
 
0.03-0.125 
 
 
 
 
0.12-0.125 
 
L (ERY,ROX) 
 
(52) 
 
P99Q 
mutation 
L22 
 
0.25 
 
0.125   0.06 
 
L (ERY) 
 
(52) 
 
A93E+P91S+ 
G83E 
mutations 
L22 
 
0.5 
 
0.03 
 
 
 
 
 
0.25 
 
L(TEL) 
 
(52) 
 
92VRPR93 
insertion  
L22 
 
2 
 
0.125 16  2 
 
C 
 
(275) 
 
G95D,G71R 
mutations 
 
L22, L4 
 
 
0.25 
 
 
0.06 
 
 
 
 
 
 
 
 
0.06 
 
 
L (AZM) 
 
 
(52) 
 
A93E+ 
C2611A 
mutations 
L22,  
Domain V 
  
0.5 
 
 
 
0.06 
 
 
 
 
 
 
0.125 
 
 
L (ROX) 
 
 
(52) 
 
 
* Domain V or II refers to domain numbers in 23S rRNA, L4 or L22 refers to ribosomal proteins. **abbreviations in 
paracenthesis after the laboratory isolates indicate which antimicrobial selected the type of mutation: clarithromycin (CLA), 
roxithromycin (ROX), otherwise as stated in the table legend.* **rokitamycin  MICs 2->32 mg/L, ****non-susceptible to 
linezolide and chloramphenicol, *****rokitamycin MIC 1 mg/L 
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Figure 2. Proportion of erythromycin non-susceptible S. pneumoniae isolates 
in countries participating in EARSS in 2005.  
(source: http://www.rivm.nl/earss/) 
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Figure 3.  Proportion of penicillin non-susceptible pneumococci in European 
countries participating in EARSS in 2005.  
(source: http://www.rivm.nl/earss/).  
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Figure 4.  Proportion of penicillin-resistant pneumococci in European 
countries participating in EARSS in 2005. 
(source: http://www.rivm.nl/earss/).  
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2. Aims of the study   
 
The aims of this study were as follows: 
 
1. To assess the prevalence of pneumococci non-susceptible to antimicrobials 
commonly used in Finland for treatment of pneumococcal infections, with 
special reference to macrolides; 
 
2. To evaluate the level of telithromycin non-susceptibility among pneumococci 
prior to widespread telithromycin usage in Finland; 
 
3. To determine the genetic basis of macrolide resistance in pneumococci  
 
4. To examine the time trends of antimicrobial resistance in invasive 
pneumococci in Finland. 
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3. Materials and methods 
3.1 Bacterial isolates 
MILL-TELI02 collection (publications I-III): Clinical laboratories (n = 24) 
were asked to collect 50 consecutive clinical S. pneumoniae isolates and send 
the isolates to the Antimicrobial Research Laboratory of the National Public 
Health Institute (KTL) with the following information: laboratory ID, age and 
gender of the patient, date of isolation, and sample type. The participating 
laboratories belonged to the FiRe network (Finnish Study Group for 
Antimicrobial Resistance), which covers the whole country and all hospital 
districts. Nineteen laboratories out of 24 (79%) sent a total of 1007 S. 
pneumoniae isolates (2-68 isolates per laboratory) between May and December 
2002. Of the 1007 isolates, 878 (87%) were from non-invasive and 129 (13%) 
from invasive infections. Non-invasive isolates were derived from ears (n = 
367), sinuses (n = 205), sputum or trachea (n = 107), eyes (n = 84), pus (n = 
67) and bronchus (n = 48). The first three publications of this thesi are based on 
all these isolates (I) or a subset of the isolates of this collection (II-III). 
 
Invasive pneumococcal collection 2002-2006 (publication IV): The 
bacterial population in this study consists of all invasive S. pneumoniae 
isolates (n = 3571) collected by clinical laboratories in Finland during the 
period of 2002-2006. Of these, 3423 (96%) were blood isolates and 148 (4%) 
were cerebrospinal fuild (CSF) isolates. Clinical laboratories sent the isolates 
to the Culture Collection of the National Infectious Disease Register of the 
KTL. The following information was provided with each isolate: date of 
isolation, laboratory ID, specimen type (blood or CSF) and the date of birth 
of the patient. The number of isolates per year ranged from 574 to 753. The 
number of bacterial isolates sent to the Culture Collection corresponded 
97.8% to the number of blood and CSF pneumococcal isolates notified to the 
National Infectious Disease Register during the same period. 
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3.2 Identification of pneumococci and serotyping 
The primary identification of S. pneumoniae was performed using conventional 
methods in clinical laboratories and was based on colony morphology, typical 
greenish alpha-haemolysis on 5% sheep blood agar (Oxoid Ltd., Basingstoke, 
Hampshire, United Kingdom), and optochin susceptibility (Optochin disk, 
Oxoid, Ltd.). Identification was further confirmed with a Slidex Pneumo-Kit 
(bio-Mérieux SA, Marcy l’Etoile, France), serotyping, or molecular methods 
when necessary. Serotyping was performed by latex agglutination for the 
neutral serogroups/types 7 and 14, followed by counterimmunoelectrophoresis 
with pneumococcal omni, pool, group/type and factor sera (Statens Serum 
Institut, Copenhagen, Denmark). The Quellung reaction was used as a 
confirmation method when needed (161, 207).  
3.3  Testing antimicrobial susceptibility 
Agar plate dilution method: The minimum inhibitory concentration (MIC) 
of an antimicrobial was determined by an agar plate dilution technique 
according to a previously described method (275). Briefly, a bacterial 
suspension corresponding to a 0.5 McFarland standard was prepared from a 
fresh overnight culture. It was further diluted 1:10 to reach a final inoculum 
concentration of 107 CFU/ml. An aliquot of each inoculum was applied to the 
surface of Mueller-Hinton II agar (Becton Dickinson Microbiology Systems, 
Cockeysville, Md., USA) with a 3 mm multipoint inoculator (Denley, Mast 
Labs, Liverpool, England) to reach a final inoculum 104 CFU per spot. Agar 
plates were prepared as instructed by the CLSI guidelines. Testing media 
were supplemented with 5% (v/v) of sheep blood for all antimicrobials 
except for testing SXT susceptibility, for which 2% (v/v) defibrinated horse 
blood was used. Plates were incubated at 35 °C supplemented with a 5% CO2 
atmosphere for 18-20 hours. The MIC was recorded as the lowest 
antimicrobial concentration that completely inhibited bacterial growth. 
Telithromycin powder was kindly provided by Sanofi-Aventis (Romainville, 
France). Other antimicrobials were purchased from their respective 
manufacturers: penicillin, tetracycline, erythromycin, clindamycin, 
ceftriaxone, SXT (Sigma-Aldrich Chemie GmbH, Steinheim, Germany), 
azithromycin (Pfizer Inc., New York, N.Y.), levofloxacin (Hoechst Marion 
Roussel [Sanofi-Aventis], Romainville, France), and meropenem 
(AstraZeneca, London, UK).  Breakpoints given for pneumococci by the 
CLSI (66) were used, with the exception of azithromycin, for which the 
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following breakpoints were used: S  1 mg/L, I = 2 mg/L, R  4 mg/L (Table 
3). S. pneumoniae ATCC 49619 and S. aureus ATCC 29213 were used as 
quality controls in each run. 
 
Further testing of telithromycin susceptibility (publications II, IV): In 
addition to agar plate dilution testing, telithromycin susceptibility testing was 
performed for 210 erythromycin non-susceptible pneumococci with a known 
macrolide resistance determinant [88 with erm(B), 4 with erm(B)+mef(E), 
104 with mef(A/E), and 14 with a mutation] and 47 randomly-selected 
erythromycin-susceptible pneumococci by the CLSI disk diffusion method 
using 15 g telithromycin disks (Oxoid Ltd., Bansingtone, Hampshire, 
England). Breakpoints for telithromycin susceptibility in disk diffusion test 
were as follows: R  15 mm, I 16-18 mm, S  19 mm. (66). If colonies were 
detected inside the growth inhibition zone (indicating heterogeneous 
resistance to telithromycin), one colony was picked (termed the zone isolate), 
streaked onto a blood agar plate and incubated for 18-20 h at 35 °C in a 5% 
CO2 atmosphere. After confirming that the zone isolate was the same species, 
it was stored at -70 C until susceptibility testing was performed with the 
same method. Susceptibility testing was repeated 3-5 times for isolates 
showing heterogeneous resistance to telithromycin in the disk diffusion test. 
Telithromycin MICs of the isolates showing heterogeneous resistance to 
telithromycin and their respective zone isolates were also determined by the 
CLSI broth microdilution in a normal atmosphere (66) and by agar plate 
dilution in 5% CO2 to compare the MICs of the isolates with these two 
methods. The ATCC strains mentioned above were used as quality controls.    
 
Investigating the stability of the telithromycin resistance (publication II): 
A serial passage method was used to test the stability of telithromycin 
resistance of three zone isolates (zone isolates, see paper II p. 1855). Isolates 
were cultured on 5% sheep blood agar plates (35 C in 5% CO2). After 
overnight incubation, sub-isolates were cultured again onto a new blood agar 
plate. The procedure was repeated five times on consecutive days. The 
susceptibility of telithromycin of each five sub-culture isolates was tested by 
the disk diffusion method as described above.  
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3.4 Detecting macrolide resistance determinants  
Polymerase chain reaction PCR (publications I, IV): Detection of 
macrolide resistance genes, mef, erm(B), and erm(A) – [erm(TR) subclass] - 
was performed by a multiplex PCR method as described previously (123). 
Separate PCR reactions were run to differentiate efflux gene subclasses 
mef(A) and mef(E) in mef-positive strains and to detect the presence of 
msr(D). Briefly, bacterial cells for PCR were harvested from fresh overnight 
culture and lysed by incubating for 10 minutes at 95 ºC to isolate the total 
DNA. AmpliTaq DNA polymerase enzyme (Applied Biosciences, Foster 
City, Ca.) was used for all PCR reactions. The MgCl2 concentration was 2 
mM in multiplex PCR and 1.5 mM in other PCR reactions. Multiplex PCR 
included initial denaturation at 94 °C for 10 min, followed by 39 cycles of 
denaturation at 94 °C for 30 s, annealing at 51 °C for 30 s and elongation at 
72 °C for 1 min. In other PCR reactions the annealing temperature was 56 °C 
for detecting mef(A) and msr(D), and 58 °C for mef(E). The number of cycles 
was 35; otherwise conditions were similar to those in multiplex PCR. All 
PCR reactions were run with a Whatman Biometra thermocycler (Biometra, 
Goettingen, Germany). Strains known to be positive for the respective 
determinant were included with every run as positive controls and a PCR 
mixture with nuclease-free water instead of bacterial DNA was used as a 
negative control. The primers are listed in Table 2.  
 
Bacterial isolates investigated using this method included 261 pneumococci 
of the MILL-TELI02 (I). Of these, 217 were non-susceptible to 
erythromycin, three were erythromycin susceptible (MIC  0.5 mg/L) but had 
low-level resistance to clindamycin (MIC 2-4 mg/L) and azithromycin (MIC 
4-8 mg/L), and 41 isolates, which were randomly selected, were susceptible 
to all macrolides, clindamycin and telithromycin. Of the invasive 
pneumococcal isolates from the 2002-2006 collection (IV) we screened 223 
erythromycin non-susceptible pneumococci for the presence of macrolide 
resistance genes.  
 
Detection of mutations conferring macrolide resistance (publications I, II): 
Mutations at positions 2058-2059 and 2611 of domain V and in loop 35 of 
domain II of 23S rRNA were detected by a pyrosequencing technique (296, 
297). Mutations in genes encoding 50S ribosomal proteins L4 and L22 were 
searched for by sequencing as previously described (183, 333). Primers used 
for pyrosequencing and sequencing are listed in Table 2. Sequencing was 
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performed using an ABI Prism BigDye Terminator Kit (Applied Biosystems) 
according to the manufacturer's instructions. The sequences were analysed 
using Vector NTI Suite 8 software (InforMax Inc, Bethesda, MD, USA). 
Comparison of sequences was performed with the sequence similarity and 
homology searching tools (Proteomes & Genomes Fasta) using a WWW 
interface to the European Bioinformatics Institute (EBI) genome database.  
 
Ribosomal mutations Domain V and II of 23S RNA and in genes encoding 
ribosomal proteins L4 and L22 were screened from those macrolide-resistant 
isolates that did not carry resistance genes (n = 18, MILL-TELI02 collection, 
pubIication I). In addition, one isolate with mef(E) and one with a double 
mechanism of mef(E) and erm(B) were investigated. These mutations were 
also screened for some selected telithromycin resistant isolates as well as 
their zone isolates (publication II).  
 
Sequencing of the 23S rRNA gene and erm(B): The whole 23S rRNA gene 
as well as the erm(B) gene with its promoter region (beginning 280 base pairs 
upstream from the start of the ErmB methylase protein coding region) were 
amplified and sequenced from some selected telithromycin resistant isolates 
in order to investigate possible mutations in these genes (see publication II). 
Primers and conditions for 23S rRNA PCR and sequencing have been 
described elsewhere (183, 333); erm(B) sequencing primers are listed in 
Table 2. For erm(B) amplification the PCR mixture had a total volume of 50 
μl, containing 10 pmol of each erm(B) PCR primer, 2 U of Ampli Taq Gold 
DNA polymerase (Applied Biosystems, Foster City, CA, USA), 1.5 mM of 
MgCl2, 5 μl of -10 x PCR buffer, 10 pmol of nucleotides, and 5 μl of DNA 
template. The PCR conditions were as follows: initial denaturation at 94 C 
for 15 min, followed by 35 cycles of denaturation at 94 C for 30 s, annealing 
at 56 C for 30 s, and extension at 72 C for 60 s. Sequencing and data 
analysis were performed as mentioned above. 
3.5 Investigating the genetic relatedness of the isolates 
Pulsed-field gel electrophoresis analysis (publication III): Pulsed-field gel 
electrophoresis (PFGE) analysis was performed for all telithromycin resistant 
isolates, three zone isolates (see publication II, page 1855) and 22 randomly 
selected erm(B)-positive telithromycin-susceptible isolates from the MILL-
TELI02 collection. Published methods were followed in the preparation of 
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bacterial genomic DNA for PFGE analysis (228) and in performing PFGE 
(219). Restriction endonuclease SmaI (New England BioLabs, Inc., USA) 
was used for digestion. DNA fragments were separated in a 1.2% PFGE-
agarose gel with a CHEF DRR III system (Bio-Rad, Hercules, CA, USA). 
Gels were stained with 1 μg/ml ethidium bromide solution and photographed 
under UV light. Dendrograms and cluster analysis were performed using the 
BioNumerics software package (Applied Maths, Inc., Austin, TX). Strains 
having PFGE profiles with  85% similarity (UPGMA, Dice coefficient) 
were considered as clones.  
 
Multilocus sequence typing (publications III, IV): MLST was performed 
for all isolates with heterogeneous resistance to telithromycin and all invasive 
isolates from 2002-2006 that were penicillin resistant according to a slight 
modification of a published method (103). Briefly, bacterial isolates were 
cultured on to 5% sheep blood agar and grown overnight at +35 °C in 5% 
CO2.  Bacterial genomic DNA was isolated from 1 μl of fresh overnight 
culture with a Dneasy Tissue Kit (QIAGEN GmbH, Germany). 
Approximately 450 base pair fragments of seven housekeeping genes were 
amplified by PCR: aroE (shikimate dehydrogenase), ddl (D-alanine-D-
alanine ligase), gdh (glucose-6-phosphate dehydrogenase), gki (glucose 
kinase), recP (transketolase), spi (signal peptidase I) and xpt (xantine 
phosphoribosyltransferase). The primers used are listed in Table 2. The PCR 
products were purified using the QiaQuick PCR purification kit (QIAGEN 
GmbH, Germany). The amplicons were sequenced on both strands. The 
sequences were analyzed using the program Vector NTI version 10 
(Invitrogen Corporation, California, US) and the results were compared with 
the MLST database, after which the sequence types (STs) were assigned. The 
STs were compared with those in the MLST database and the clonal complex 
group for each strain was determined by E-burst analysis. The method and 
database are available via the MLST website (www.mlst.net). 
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 Table 2. Primers used in the study 
Sequence(5'-3') 
Target Use** 
Forward Reverse 
Reference 
 
mef(A/E) 
 
multiplex-PCR 
 
GGCAAGCAGTATCATTAATCAC 
 
GACTGCAAAGACTGACTATAG 
(123); this work
 
erm(B) 
  
multiplex-PCR 
 
 
GAAAARGTACTCAACCAAATA 
 
AGTAAYGGTACTTAAATTGTTTAC 
 
(326) 
 
erm(A) 
 
multiplex-PCR 
 
CTTGTGGAAATGAGTCAACGG 
 
TTGTTCATTGGATAATTTATC (275) 
 
mef(E) 
 
PCR 
 
GGGAGATGAAAAGAAGGAGT 
 
GCTATAAAATGGCACCGAAAG 
 
(77); this work 
mef(A) PCR TGGTTCGGTGCTTACTATTGT CCCCTATCAACATTCCAGA (64) 
 
msr(D) 
 
PCR 
 
CAGTTGGACGAAGTAACTCTG 
 
CTCTTACGTTCTTCCTCTTTC 
 
(77); this work 
 
L4 ribosomal protein 
 
PCR/seq 
 
AAATCAGCAGTTAAAGCTGG 
 
GAGCTTTCAGTGATGACAGG 
 
(333) 
L22 ribosomal protein 
 
PCR/seq 
 
GCAGACGACAAGAAAACACG 
 
ATTGGATGTACTTTTTGACC (333) 
 
PCR 
 
 
TAAGGTAGCGAAATTCCTTGTCG 
 
 
CGACCGCCCCAGTCAAACT** 
 
(143) 
 
Domain V 23S rRNA, 
position 2058-2059 
 Pyroseq GGTTACCCGCGACAGGACGG 
 
(143) 
 
Domain V 23S rRNA, 
position 2611 
 
 
PCR 
 
Pyroseq 
 
TGGGTTCAGAACGTCGTGAGA 
 
CGTGAGACAGTTCGGTC 
 
GCGGTAAGTCCACTCTGGTC** 
 
 
 
This work 
 
 
 
Whole erm(B) 
 
 
PCR 
 
GAAGCAAACTTAAGAGTGTG 
 
GCTAGGGACCTCTTTAGCTT 
 
This work 
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 Table 2. Primers used in the study 
Seq CAGTGATTACGCAGATAAATA GACACGAATGTTCAGTTTTA This work 
Seq CCTAAACCAAAAGTAAACAG TCTCGATTGACCCATTTTGA This work 
PCR GCGCCTTAGTATCATGACGTAGA AATGTCGACGCTAGCCCTAAAG** This work 
Pyroseq CGCTACCCACAAGTCA  This work 
 
Loop 35 of domain II 
Pyroseq CGTGAGACAGTTCGGTC  This work 
 
Shikimate  
dehydrogenase (aroE) 
 
MLST 
 
 
CGTTTAGCTGCAGTTGTTGC 
 
 
CCCACACTGGTGGCATTAAC 
 
 
(102) 
 
D-alanine-D-alanine  
ligase (ddl) 
 
 
MLST 
 
 
 
TTGCCATGGATAAAATCACGA  
 
 
 
CGCGCTTGTCAAAACTTTCC 
 
 
 
Bichon B 
personal 
comm; (29) 
 
Glucose-6-phosphate  
dehydrogenase (gdh) 
MLST 
 
ATGGACAAACCAGC(G/A/T/C)AG(C/T)TT 
 
GCTTGAGGTCCCAT(G/A)CT(G/A/T/C)CC 
 
 
(103) 
 
Glucose kinase (gki) 
 
MLST 
 
GGCATTGGAATGGGATCACC 
 
TCTCCCGCAGCTGACAC 
 
(103) 
Transketolase (recP) 
 
MLST 
 
 
GAATGTGTGATTCAATAATCACC 
 
TTCGATAGCAGCATGGATGG 
 
(102) 
 
Signal peptidase I (spi) 
 
MLST 
 
CGCTTAGAAAGGTAAGTTATG 
 
AGGCTGAGATTGGTGATTCTC 
 
Bichon B, 
personal 
comm.
Xantine phosphor-
ribosyltransferase (xpt) 
MLST 
 
TTATTAGAAGAGCGCATCCT 
 
AGATCTGCCTCCTTAAATAC 
 
(103) 
 
* Seq – sequencing, Pyroseq – pyrosequencing; **Primer biotinylated
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3.6 Data analysis  
Descriptive analysis of antimicrobial resistance included the calculation of 
resistance percentages as well as the MIC50, MIC90, and MIC range when 
appropriate. Resistance percentages were calculated by using the intermediate 
breakpoint as a cut-off if not otherwise stated, except for penicillin, for which 
the proportions of penicillin non-susceptibility (PNSP, PEN I and R isolates) 
and penicillin resistance (PEN R) were calculated. An isolate showing non-
susceptibility to  3 different antimicrobial classes was defined as 
multiresistant. Resistance percentages were also calculated according to the 
age group, hospital district and University Hospital District of the cases. The 
University Hospital Districts were Helsinki-Uusimaa, (Southern Finland), 
Turku (South-Western Finland), Tampere (Central and Mid-Western 
Finland), Kuopio (Eastern Finland) and Oulu (Northern Finland). The age 
groups were 0-2 years, 3-15 years, 16-64 years and  65 years. The two first 
mentioned age groups were combined for statistical testing due to the small 
number of cases among 3-15 years in the publication IV. The chi-squared test 
was used to compare resistance percentages in non-invasive and invasive 
pneumococci (publication I) and the proportion of ceftriaxone-resistant 
isolates in 2005-2006 (publication IV). The Mann-Whitney test was used to 
compare erythromycin MICs between mef(A) and mef(E) isolates 
(publication I), and the Poisson regression was used for testing the statistical 
significance of the trends of antimicrobial resistance over the time 
(publication IV). The logarithm of the number of isolates for each day was 
incorporated as an offset. In the model, time was considered as a continous 
variable and district and age group were categorical variables. Risk ratio 
estimates (representing the relative change in the risk for a strain being 
resistant to an antimicrobial within a one-year period) and 95% CIs were 
calculated, while a P value  0.05 was considered statistically significant. 
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4. Results  
4.1 Occurrence and trends of antimicrobial resistance 
MILL-TELI02 collection (publication I) 
 
Of the 1007 S. pneumoniae isolates collected in 2002, 21.5% were non-
susceptiblel to erythromycin, 11% to clindamycin and 2.6% to telithromycin. 
The proportion of isolates non-susceptibile to penicillin, tetracycline and 
sulphatrimethoprim was 12.1%, 14.4% and 26.8%, respectively. The 
ceftriaxone non-susceptibility rate was 2.1% if the meningitis breakpoint was 
used, but only 0.1% with the non-meningitis breakpoint. Less than 1.5% of 
isolates were resistant to fluoroquinolones and only two isolates non-
susceptible to linezolide. No vancomycin-resistant isolates were detected. MIC 
data (MIC50, MIC90, range) and the distribution of the 1007 pneumococcal 
isolates among separate susceptibility categories are presented in Table 3. 
Multiresistance was detected in 10.5% of isolates (n = 106), with 6.7% (n = 67) 
of isolates resistant to four or more and 2.3% (n = 23) to five more 
antimicrobial classes. The most common multiresistant phenotype was ERY-
PNSP-TET-SXT (n = 34). Erythromycin resistance was equally frequently 
detected among non-invasive and invasive isolates. However, isolates from 
non-invasive infections were more frequently non-susceptible to penicillin and 
multiresistant (Table 4). Bronchus and ear isolates were the most resistant and 
isolates from the eyes the most susceptible (Table 5). Resistance to macrolides 
ranged among hospital districts from 6 to 38%, penicillin non-susceptibility 
from 2 to 23%, and tetracycline resistance from 4 to 33%. Figure 5 illusrates 
macrolide and penicillin non-susceptibiliy percentages by hospital district. 
Resistance percentages are presented according to age group and university 
hospital district in Tables 6 and 7, respectively.   
4. Results
 Table 3. MIC data (MIC50, MIC90, min-max) and distribution of isolates (%) among susceptibility categories (S - 
susceptible, I - intermediate, R - resistant) for 1007 pneumococcal isolates in Finland, 2002 
mg/L % of strains Breakpoints* Antimicrobial 
agent 
 MIC50 MIC90 min-max S I R 
S 
 
I 
 
R 
 
Erythromycin 0.125 64 0.016 - 128 78.5 0.4 21.1 0.25 0.5 1 
Clindamycin 0.125 2 0.008 - 128 89.0 0.6 10.4 0.25 0.5 1 
Azithromycin 0.5 128 0.063 - 128 77.7 0.4 21.9 1 2 4 
Spiramycin 1 32 0.125 - 128    ND**   
Telithromycin** 0.031 0.5 0.008 – 8 97.4 1.9 0.7 1 2 4 
Penicillin  0.016 0.125 0.008 – 4 87.9 9.2 2.9 0.063 0.125 2 
Ampicillin 0.031 0.125 0.008 – 8    ND   
Cephalexin 0.125 0.5 0.016 – 16    ND   
Cefuroxime  0.031 0.25 0.008 – 16 93.4 1.4 5.2 0.5 1 2 
Ceftriaxone 0.016 2 0.008 – 2 97.9 2.0 0.1 0.5 1 2 
Meropenem 0.008 0.125 0.008 – 1 95.7 3.9 0.4 0.25 0.5 1 
Levofloxacin 1 2 0.126 – 16 98.8 0.9 0.3 2 4 8 
Moxifloxacin 0.25 0.5 0.063 – 8 98.6 1.1 0.3 1 2 4 
Tetracycline 0.25 32 0.063 – 64 85.6 0.2 14.2 2 4 8 
Trimethoprim-
sulfamethoxazole 
 
0.25 
 
4 
0.125 – 64 
 
73.2 
 
13.6 
 
13.2 
 
0.5/9.5 
 
1/19-2/38 
 
4/76 
 
Linezolide 1 2 0.125 – 4 99.8  0.2 2   
Vancomycin 0.25 0.25 0.125 – 1 100.0   1   
*All breakpoints are acccording to CLSI standards, except for azithromycin, for which breakpoints were determined according to the MIC distribution. 
Ceftriaxone breakpoints in the table are meningitis breakpoints. Ceftriaxone breakpoints for non-meningitis isolates are as follows: S  1 mg/L, I 2 
mg/L, R 4  4 mg/L. With non-meningitis breakpoints, 99.1% of isolates were susceptible and 0.1% intermediate. **ND - breakpoints not determined by 
CLSI. **Telithromycin non-susceptibility rates presented here should be interpreted with caution because these breakpoints are for the CLSI 
microdilution method for a normal atmosphere.   
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Table 4. Comparison of erythromycin non-susceptibility, penicillin non-
susceptibility and multiresistance in non-invasive and invasive pneumococcal 
isolates in Finland, 2002. 
Non-invasive 
(n = 878) 
Invasive 
(n = 129)Resistance profile 
% 
P 2 
ERY (I+R) 22.8 20.9 0.6 0.22 
PEN (I+R) 13.6 5.4 0.014 6.02* 
Multiresistance (ERY-PEN-TET)** 8.2 1.6 0.012 6.36* 
*statistical testing performed with Yates correction, **ERY – erythromycin, 
PEN - penicillin, TET –tetracycline. I – intermediate, R – resistance 
 
Table 5. Percentage of resistance* to erythromycin (ERY), clindamycin 
(CLI), levofoxacin (LEV), tetracycline (TET) and trimethoprim-
sulfamethoxazole (SXT) of pneumococcal isolates according to specimen 
origin in Finland, 2002. 
ERY CLI PEN LEV TET SXT 
Specimen origin 
% 
Ear (n = 367) 27 14 16 1 17 31 
Sinuses (n = 205) 20 10 11 2 14 28 
Blood or CSF (n = 129) 20 9 5 0 10 19 
Sputum/trachea (n = 107) 18 8 12 1 18 20 
Eyes (n = 84) 11 7 5 5 5 20 
Pus (n = 67) 16 6 19 0 9 50 
Bronchus (n = 48) 29 13 15 0 29 37 
*Including both I (intermediate) and R (resistant) isolates 
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Table 6. Resistance* of pneumococcal isolates to 
erythromycin (ERY), penicillin (PNSP) and tetracycline 
(TET) according to age group in Finland, 2002 
ERY PNSP TET Age group 
(years) No. of  isolates % 
0 - 2    384 28.1 17.7 19.3 
3 - 15    224 14.7 8.5 7.1 
16 - 64  305 17 8.2 10.8 
 65  94 24.5 10.6 23.4 
* Includes both intermediate and resistant isolates 
 
Table 7. Percentage resistance of pneumococcal isolates according 
to University Hospital District in Finland, 2002 
 
Resistance % University Hospital District No. of isolates 
ERY PNSP TET 
Helsinki-Uusimaa  395 19.5 13.4 13.7 
Kuopio 109 25.7 11.9 14.7 
Oulu 167 28.7 19.8 20.4 
Tampere 238 13.9 4.6 8.8 
Turku 98 31.6 12.2 20.4 
Total 1007 21.5 12.1 14.4 
 
 
 
 
 
4. Results
  
Figure 5. Erythromycin and penicillin non-susceptibility of pneumococcal isolates in 
hospital districts in Finland, 2002 (MILL-TELI02 collection)  
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Antimicrobial resistance in invasive pneumococci 2002-2006 (publication IV) 
Erythromycin resistance ranged from 16% (2002) to 28% (2006) and increased 
significantly during the study period (p < 0.0001). The proportion of penicillin 
non-susceptible isolates doubled from 8% to 16% (P = 0.0002) and proportion 
of penicillin-resistant isolates increased from 0.8% to 3.7% (p = 0.03). 
Tetracycline resistance remained stable. The proportion of multiresistant 
isolates increased from 3.7% (2002) to 5.1% (2006), but this change was not 
significant (p = 0.72) (Table 8).  The resistance figures for CSF isolates were 
similar to those for blood isolates. Ceftriaxone non-susceptibility was 2.9% in 
2005 and 3.7% in 2006 (chi-squared test, p = 0.36), but MICs were low: only 
two isolates (0.3%) had an MIC of 2 mg/L in 2006, but none in 2005. Five 
isolates in 2004 (1.7%), three in 2005 (0.5%) and one in 2006 (0.1%) were 
resistant to levofloxacin. All levofloxacin-resistant pneumococci were isolated 
from older patients (median 69 years). Figure 6 illustrates the development of 
antimicrobial resistance during the study period. The figure also includes 
previously published antimicrobial resistance data from the period of 1999-
2000 (273) and unpublished data from 2001.  
 
The highest erythromycin resistance rates were detected among pneumococci 
isolated from 0- to 2-year-old children: in 2006, 45.8% of isolates were 
resistant to erythromycin in this age group. Time trend risk ratio estimates for 
erythromycin non-susceptibility by age group were as follows: 0-15 years RR 
1.12, (p = 0.01); 16-64 years RR 1.11 (p = 0.003), and  65 years RR 1.16 (p 
< 0.001). For penicillin non-susceptibility, the respective estimates are: 0-15 
years RR 1.11 (p = 0.14), 16-64 years RR 1.22 (p < 0.001) and  65 years RR 
1.15 (p = 0.01). The proportion of penicillin resistant isolates increased 
significantly in 16-64 years (RR 1.53, p < 0.001), but the trend was not 
statistically significant in any other age group. Resistance development over 
time according to age group can be seen in the publication IV, Figure 1. At 
the university hospital district level, a significant increase in erythromycin 
resistance was observed in the Tampere district, from 7% to 29% (RR 1.35, 
95% CI 1.20-1.52, p < 0.0001) and Oulu, from 20% to 28% (RR 1.12, 95% 
CI 1.00-1.25, P = 0.04). The increase of penicillin non-susceptibility was 
statistically significant in Tampere district, from 5% to 15% ,(RR 1.25, 1.07-
1.45, p = 0.004) and Kuopio district, from 5% to 20% ,(RR 1.30, 1.04-1.61, p 
= 0.02). PEN resistance increased significantly in Tampere, from 1% to 5% 
(P = 0.002), and in Kuopio, from 0% to 10% (P = 0.006). 
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Table 8. Antimicrobial resistance in invasive pneumococci in Finland at the beginning 
(2002) and the end (2006) of the study period and the relative change in resistance per 
year according to the Poisson regression model.  
Antimicrobial* 
Resistance 
percentages in the first 
and last years of the 
study period 
95% Confidence 
intervals 
  
2002 2006 
Relative 
change per 
year,        
ratio 
 
 
Lower upper 
p-value 
ERY 16.3 27.9 1.12 1.06 1.18 <0.0001 
PNSP 8.0 16.4 1.15 1.07 1.23 <0.0001 
PEN R 0.8 3.7 1.18 1.02 1.36 0.03 
TET 9.8 11.5 1.00 0.93 1.08 0.99 
ERY-PNSP-
TET 
3.7 
 
5.1 
 
1.02 0.91 1.14 0.72 
*ERY- erythromycin I+R isolates; PNSP - penicillin non-susceptibile I+R isolates; PEN R 
-  penicillin resistant isolates; TET - tetracycline I+R isolates; multiresistance (ERY-
PNSP-TET) 
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Resistance by serotype (publication IV)  
The most common serotypes in decreasing order of frequency in 2006 were 
14 (20%), 4 (11%), 6B (9%), 23F (7%), 3 (6%), 7F (6%), 19F (5%) and 9V 
(5%). The most prominent change was detected in serotype 14, the 
proportion of which increased from 14% to 20% during 2002-2006. Serotype 
14 isolates were most frequently non-susceptible to erythromycin or 
penicillin. Table 9 presents the overall frequency of different serotypes and 
the proportion of erythromycin and penicillin non-susceptible isolates in 
different serotypes during the study period.  
 
 
Table 9. The frequency of different serotypes and the rate of 
antimicrobial resistance according to serotype among invasive 
pneumococci (n=3571) in Finland, 2002-2006 
Serotype frequency 
 
Non-susceptibility (%) 
Serotype N %  ERY* PNSP** 
14 551 15.4  57.8 36.3 
4 405 11.3  4.7 3.2 
23 F  272 7.6  8.5 6.6 
9 V  268 7.5  41.8 13.4 
3 243 6.8  2.9 3.3 
6 B  250 7.0  40.2 20.8 
7 F  228 6.4  2.6 1.3 
19 A  163 4.6  41.7 11.0 
18 C  156 4.4  3.2 1.9 
19 F  155 4.3  26.5 20.6 
9 N  125 3.5  12.8 4.0 
22 F  119 3.3  5.9 2.5 
6 A 108 3.0  10.2 3.7 
12 F  97 2.7  2.1 ND 
11 A 51 1.4  5.9 ND 
Others 380 10.6  8.4 1.6 
*ERY – erythromycin non-susceptibility, include both intermediate and 
resistant isolates. **PNSP – penicillin non-susceptible pneumococci, 
include intermediate and resistant isolates. 
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Clonality results for penicillin-resistant invasive pneumococci 2002-2006 
(publication IV) 
 
Multilocus sequence typing was performed for 88 penicillin-resistant 
invasive pneumococci in 2002-2006. Table 10 summarises the results of 
MLST typing of these pneumococci. See Table 3 in publication IV, for more 
detailed results. In summary, a total of 25 sequence types were found that 
distributed into ten clonal lineages (clonal complexes, CC). In addition, two 
singletons (ST3248, ST3249) were observed that have not previously been 
described outside Finland. The most common clonal complex was CC156, 
accounting for 61% of all penicillin-resistant isolates, followed by CC271 
(10% of the isolates) and CC81 (9% of the isolates). This means that the 
majority of the penicillin-resistant pneumococci in this study were 
representatives or single to triple locus variants of the following PMEN 
clones: Spain9V ST156, Taiwan19F ST236, Spain23F ST81, and England14 ST9. 
Other international clones or closely related strains occurring among 
penicillin-resistant pneumococci were England14 ST9, Spain6B ST90, 
Sweden15A ST63, and Sweden4 ST205.   
4. Results
   
 
Table 10. Occurrence of different clonal complexes and sequence types among penicillin-resistant invasive 
pneumococci (n = 88) in Finland, 2002-2006 
Clonal 
complex  N % Secuence types (n) PMEN clone and its variants* 
CC156 
 
 
54 
 
 
61.4 
 
 
ST156 (29), ST2306 (11) , ST143 
(7), ST2916 (4), ST2918 (1), ST3247 
(1), ST671 (1) 
Spain9V ST156 + its SLVs, DLVs and 
TLVs 
 
CC271 
 
9 
 
10.2 
 
ST2917 (3), ST271 (2), ST236(2), 
ST2694 (1), ST3245 (1) 
Taiwan19F ST236 + its SLVs and DLVs 
 
CC81 
 
8 
 
9.1 
 
ST961 (5), ST81 (2),  
ST3250 (1) 
Spain23F ST81 + its SLVs 
  
CC15  4 4.5 ST13 (4) SLV of England14 ST9 
CC146 4 4.5 ST90 (3), ST3246 (1) Spain6B ST90 + its DLVs 
CC63 2 2.3 ST2678 (2) 
 
SLV of Sweden15A ST63 
CC205 1 1.1 ST205 (1) Sweden4 ST205 
CC496 2 2.3 ST496 (2) None 
CC138 1 1.1 ST138 (1) None 
CC460 1 1.1 ST461 (1) None 
Singleton 1 1.1 ST3248 (1) None 
Singleton 1 1.1 ST3249 (1)  None 
PMEN = Pneumococcal Molecular Epidemiology Network,  *SLV = single locus variant, DLV = double locus 
variant, TLV = triple locus variant 
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4.2    Macrolide resistance determinants (publications I, IV) 
 
The most frequent macrolide resistance mechanism in 2002 (publication I) 
was the mef gene, which was present in 49% (107/220) of macrolide-resistant 
isolates, while the respective frequency of erm(B) was 41% (Table 11). 
msr(D) was present in all mef-positive isolates.  Altogether, 89% of mef 
isolates (n = 95) had the mef(E) subclass and 11% (n = 12) had mef(A). 
Erythromycin MICs of the mef(A)-positive strains were higher than those of 
the mef(E) strains (geometric means 32 and 10.9 mg/L, respectively, p = 
0.002, Mann-Whitney U-test). Mutation was detected in 16 isolates, of which 
14 isolates had no other known resistance factor. Six new ribosomal protein 
mutations were found that had not previously been described in clinical 
isolates. Of these, four mutations were in the L4 protein (68E69, 68GQK69, T94I, 
V205G) and two in the L22 protein (R22C, A101P). Pneumococcal strains with 
mutations and their phenotypes are presented in the Table 1 of the publication 
I on page 4181. Figure 7 (right panel) shows the distribution of erythromycin 
MICs according to the macrolide resistance determinant.  
 
Table 11. Macrolide resistance mechanisms in pneumococci 
in Finland, 2002 
Mechanism n % 
mef(E) 95 43.2 
mef(A) 12 5.5 
erm(B) 90 40.9 
mef(E) + erm(B) 5 2.3 
erm(A) 1 0.5 
Mutation only* 14 6.4 
Unknown  3 1.4 
*Altogether, 16 strains had a mutation, but a macrolide 
resistance gene was present in two of them 
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In the invasive pneumococcal collection from 2002-2006 the mef gene was also 
the most common macrolide resistance determinant, and was detected in 56% 
(n = 125) of the investigated isolates (n = 223). erm(B) was present in 31% (n 
= 69) of the isolates and both mef(E) and erm(B) were carried by two isolates 
(0.9%). Of the mef-positive isolates which were further investigated (n = 60), 
72% (n = 43) were mef(E) and 28% (n = 17) mef(A). All mef(A) isolates 
belonged to serotype 14 and were susceptible to penicillin. In 28 isolates the 
macrolide resistance mechanism remained unknown. In contrast to the MILL-
TELI02 collection there were no significant differences in ERY MICs of the 
invasive pneumococci between the mef(A) and mef(E) isolates, although the 
geometric mean of the ERY MIC was slightly higher in mef(A)-positive 
isolates compared to that of mef(E) isolates (36.2 mg/L vs. 28.1 mg/L). There 
was no indication of a right shift in ERY MICs in mef-positive strains. 
4.3 Telithromycin resistance  
MIC, zone size distribution and resistance genes (publication I) 
In the MILL-TELI02 collection, telithromycin MICs ranged from 0.008 to 8 
mg/L; 2.6% of isolates had an MIC  2 mg/L (Table 3). The isolates formed 
two distinct populations (Figure 7, left panel), of which larger population 
(83% of isolates) had an MIC range from  0.008 to 0.063 mg/L and the 
smaller population (17% of isolates) from 0.125 to 8 mg/L. Telithromycin 
MICs in relation to the macrolide resistance determinant are illustrated in 
Figure 7 and respective zone sizes are presented in publication II, Table 1, 
page 1856. 
Heterogeneous resistance to telithromycin (publications II, IV) 
In disk diffusion testing, 26 pneumococcal isolates produced one to several 
clearly visible colonies inside the growth inhibition zone, indicating 
heterogeneous resistance to telithromycin (publication II). The typical growth 
pattern of such isolates can be seen in publication II, Figure 1, p. 1856. All 
isolates showing colonies inside the inhibition zone were classified as 
resistant to telithromycin, regardless of the zone size. Susceptibility testing 
demonstrated that the phenomenon was repeatable, but the number of 
colonies inside the inhibition zone varied. All isolates with heterogeneous 
resistance to telithromycin were erm(B) positive and two of them also carried 
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mef(E). We also subcultured colonies growing inside the growth inhibition 
zone and tested their telithromycin susceptibility. Figure 1 of publication II 
on p. 1856 illustrates the typical narrow inhibition zone of a zone isolate. In 
these isolates, telithromycin resistance was observed to be constant and did 
not diminish in five serial passages. The mean diameter of the inhibition zone 
of the pneumococci (publication II) with heterogeneous resistance was 20.9 
mm (range 15 – 24 mm), whilst the respective diameter in sub-isolates grown 
from colonies picked from inside of the inhibition zone (i.e. zone isolates, 
n = 26) was 8.3 mm (range 6 – 19 mm). Of the zone isolates, 23 were 
classified as resistant and two as intermediate. One zone isolate had an 
inhibition zone diameter of 19 mm.  
 
Among invasive pneumococci collected in 2002-2006, heterogeneous 
telithromycin resistance was detected in 9 out of 128 (7%) erythromycin 
resistant isolates tested with the disk diffusion test.  
Comparison of telithromycin MICs between agar plate and broth 
microdilution methods (publication II) 
Telithromycin MICs of isolates showing heterogeneous telithromycin 
resistance in the disk diffusion test and their respective zone isolates were 
determined concurrently by the CLSI broth microdilution method in ambient 
air and by the agar dilution in a 5% CO2 atmosphere. The telithromycin 
MIC50 and MIC90 of the isolates showing heterogeneous resistance to 
telithromycin were 2 and 4 mg/L (range 0.063 to 8 mg/L), respectively, when 
measured by the agar dilution method (Table 12). With the broth 
microdilution method the respective values were 0.125 and 1 mg/L (range 
0.063 – 2 mg/L). Thus, all but one isolate with heterogeneous resistance to 
telithromycin would have been classified as susceptible according to current 
breakpoints with the broth microdilution method in a normal atmosphere. 
The telithromycin MIC50 and MIC90 of the zone isolates was 32 mg/L and 64 
mg/L, respectively, according to the agar dilution method in 5% CO2, whilst 
they were 4 and 8 mg/L with CLSI broth microdilution in ambient air. Three 
zone isolates failed to grow with the latter method (Table 12).  
4. Results
 Table 12. Comparison of telithromycin MICs of isolates showing heterogenous resistance and their respective 
zone isolates determined with the agar dilution and CLSI broth microdilution methods 
erm(B) isolates with heterogeneous resistance* 
  
zone isolates** 
 
Agar dilution 
method in 5% 
CO2 
 
CLSI Broth 
microdilution 
method 
Agar dilution 
method in 5% 
CO2 
CLSI Broth 
microdilution 
method 
n = 26 n = 24*** n = 26 n = 23*** 
  
Parameter 
  
Telithromycin MIC (mg / L) 
Geometric 
mean 
1.89 
 
0.15 
 
33.8 
 
2.87 
 
Min – max 
 
0.063-8 
 
0.063-2 
 
4-64 
 0.125-8 
MIC50 
 
2 
 
0.125 
 
32 
 
 
4 
MIC90 4 1 64 8 
 
No. of isolates 
with MIC  2 
mg/L (%) 
21 (81%) 
 
1 (4%) 
 
  
26 (100%) 
 
21 (91%) 
 
* Isolates having a visible inhibition zone but individual colonies detected inside this zone  
** Zone isolates were derived from individual colonies from inside the inhibition zone 
***Some isolates did not grow with the microdilution method in a normal atmosphere 
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Tracing the possible mechanism for telithromycin resistance (publication II) 
 
The erm(B) gene and its promoter region (beginning 280 base pairs upstream 
from the start of the ErmB methylase protein coding region) were sequenced 
for three telithromycin-resistant isolates and their respective zone isolates (# 
547, 415, 1022 and 547V, 415V 1022V). Genes encoding 50S ribosomal 
proteins L4 and L22 of the above-mentioned six isolates were also sequenced 
and ribosomal mutations in domains V and II of 23S rRNA were detected by 
pyrosequencing. In addition, the whole 23S rRNA gene of one telithromycin-
resistant isolate and the respective zone isolate (#547, 547V) were sequenced. 
The nucleotide sequences of erm(B) and its promoter area, positions 2058-
2059 and 2611 of domain V, and loop 35 of domain II of 23S rRNA, as well 
as genes encoding 50S ribosomal proteins L4 and L22, were identical to 
heterogeneously telithromycin-resistant isolates and zone isolates. No 
mutations known to confer resistance in the promoter area of erm(B), in 23S 
rRNA genes or in genes coding for L4 or L22 were detected. The consensus 
sequences of 23S rRNA for 547 and 547V had 99.97% and 99.83% similarity 
with published genomic 23S rRNA sequences of S. pneumoniae strains 
TIGR4 and R6, respectively. Thus, no mechanisms known to be associated 
with telithromycin resistance were identified in this study.  
Genetic relatedness of the telithromycin-resistant isolates (publication III) 
The clinical characteristics, PFGE profiles and sequence types (STs) of the 
heterogeneously telithromycin resistant pneumococci (n = 26) are 
summarized in Paper III, Table 1, p. 1885. The isolates originated from both 
invasive and non-invasive infections in twelve hospital districts of Finland. 
These areas cover all parts of Finland except for Lapland. The patients’ mean 
and median ages and age ranges were 16.5, 2 and 0-84 years, respectively. 
Fifteen isolates were obtained from female patients and ten from males. 
Penicillin non-susceptibility (MIC  0.125 mg/L) was less frequent among 
erm(B)-positive isolates showing heterogeneous resistance to telithromycin 
(4/26) than among erm(B)-positive but telithromycin-susceptible isolates 
(50/66) (p < 0.0001, Fisher’s exact test). Tetracycline resistance (MIC  4 
mg/L) alone was as frequently observed among erm(B)-positive 
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telithromycin-resistant isolates as among erm(B)-positive telithromycin-
susceptible pneumococci. None of the isolates was resistant to levofloxacin 
or linezolid. Serotype 19A was the most frequent serotype. The PFGE 
dendogram is presented in Paper III, Figure 1, page 1886. Overall, erm(B)-
positive telithromycin-susceptible pneumococci were more heterogeneous 
compared to erm(B)-positive telithromycin-resistant isolates. Twenty-six 
telithromycin resistant isolates were distributed into seven distinct PFGE 
types, of which type A was the most frequent with 19 telithromycin-resistant 
isolates. Three subtypes were detected among those isolates with the type A 
pattern, but 14 isolates belonged to subtype A1. Four telithromycin 
susceptible isolates had a PFGE pattern closely related to telithromycin-
resistant strains. Three zone isolates had an identical PFGE pattern to their 
respective parent isolates. Twenty-three telithromycin-susceptible erm(B) 
isolates were distributed among twelve distinct PFGE types. MLST results 
were in accordance with the PFGE results: telithromycin-resistant isolates 
had seven distinct sequence types. Of these, ST2248, 2306 and 2307 were 
novel types. The other four sequence types were ST193, 133, 271 and 271, of 
which ST193 was the most prevalent and corresponded to PFGE type A. 
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Figure 6. Resistance development in invasive pneumococci in Finland during 
1999-2006. Percentage resistance is indicated on the y axis. The number of 
isolates tested per year ranged from 360 to 753. *The results from 1999-2000 
are from a previously published report by Pihlajamaki et al. (AAC, 2002) and 
the data from 2001 are previously unpublished. ERY – erythromycin, PEN – 
penicillin, TET – tetracycline, I – intermediate, R – resistant; multiresistance: 
non-susceptibility to ERY-PEN-TET.  
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Figure 7. Left panel: distribution of telithromycin MICs, right panel: 
distribution of erythromycin MICs of 1007 clinical pneumococci. Bar 
symbols: oblique – strains susceptible to macrolides; dark grey – strains with 
mutations; pale gray – strains with mef(A) or mef(E); black – strains with 
erm(B) or erm(A); white – strains with double mechanism erm(B)+mef(E). 
 
5. Discussion 
5.1 Macrolides 
Resistance 
Of the 1007 S. pneumoniae isolates collected in 2002 from a variety of 
infections in Finland (MILL-TELI02 collection), one fifth were resistant to 
erythromycin. Azithromycin resistance percentage was slightly higher 
(22.3%) than the respective figure for erythromycin. The minor difference 
can be explained by the presence of some mutated strains that showed 
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azithromycin non-susceptibility but were erythromycin susceptible. 
Therefore it can be concluded that the azihtromycin breakpoints adjusted for 
our method worked well. Azithromycin and clarithromycin resistance 
percentages are usually close to that of erythromycin (181, 292) and could be 
considered as indicators of erythromycin resistance. The proportion of 
clindamycin-resistant isolates was half of that for erythromycin-resistant 
isolates in this study. This result reflects the distribution of macrolide 
resistance genes in Finland, since the major resistance mechanism was drug 
efflux encoded by the mef gene, which does not cause resistance to 
clindamycin (218). The highest antimicrobial non-susceptibility figures were 
observed among pneumococci isolated from from children aged 0-2 years, 
which is in accordance with many other studies (44, 90, 107). This is most 
likely due to the high antimicrobial consumption among this age group (13).  
 
Pneumococcal isolates of non-invasive origin are often more resistant to 
antimicrobials than invasive isolates (137, 193, 266, 340). Apart from 
erythromycin resistance, similar observations were recorded in our study. 
The difference might be explained by the fact that bacteriological cultures are 
more often performed in the early phase of infection in the case of invasive 
infections. Varying resistance figures in pneumococci of different origin can 
also reflect differences in the use of antimicrobials for treating various 
infections. This is supported by the fact that pneumococcal isolates from the 
eye were most commonly susceptible to erythromycin but most frequently 
resistant to fluoroquinolones. Topical fluoroquinolones, on the other hand, 
are commonly used to treat eye infections, while macrolides are not.  
 
Results based on invasive pneumococci isolated in 2002-2006 demonstrated 
a significant increase in erythromycin resistance from 16 to 28%. Compared 
to the period from 1999-2000, the increase in erythromycin resistance was 
almost five-fold (273). Erythromycin resistance rates similar to Finland (20-
30%) have been reported from Germany (22%), the UK (24%), Switzerland 
(29%) (107) and Ireland (22%) (291). Finland has a higher prevalence of 
resistance among pneumococci than its neighbouring countries. For example, 
in Norway approximately 4% of over 9000 pneumococcal isolates collected 
in 1995-2005 were non-susceptible to erythromycin, although an increase in 
resistance from 1.7% in 1995 to 10.6% in 2005 was detected during the study 
period (319). Sweden, on the other hand, is an example of a country where 
the proportion of erythromycin-resistant pneumococci has remained low. 
This is most likely because of a successful conservative antimicrobial policy 
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leading to a reduced consumption of antimicrobials, especially macrolides 
(243). According to Swedish national surveillance data, less than 5% of 
pneumococci were resistant to erythromycin in 2007 
(http://www.srga.org//ResNet). This also applies to Estonia and Russia (5, 
107, 214). Countries with a low prevalence of macrolide resistance (<10%) 
also include the Czech Republic, Portugal, the Netherlands, and Denmark 
(107, 293). In Great Britain, slightly higher erythromycin resistance rates 
have been detected, ranging from 9 to 14% depending on the data source 
(221). Today, the highest erythromycin resistance prevalences in Europe (44-
53%) occur in France, Greece, Italy and Hungary, followed by Spain (34%) 
(107). Globally, almost 40% of pneumococci were erythromycin resistant in 
2003-2004 (107), the highest resistance rate being in the Far East (~80%) and 
the lowest in Northern Europe and Latin America (~15-18%) (120). In the 
USA, the prevalence of erythromycin resistance in 2000-2004 was ~30%, 
ranging from 17% (south-west region) to 39% (south-central region) (187). 
Regional differences were also observed in our studies. In 2002, 
erythromycin resistance varied among university hospital districts from 14 to 
32%, being lowest in Tampere and highest in Turku according to the results 
from the MILL-TELI02 collection. The results for invasive pneumococci in 
were in accordance with resistance levels recorded in 2002, although 
erythromycin resistance was somewhat lower. Thereafter, resistance 
increased most rapidly in Tampere district, followed by Kuopio and Oulu 
districts. By 2006, regional differences had declined, although the highest 
prevalence of resistance was still recorded in Turku.  
Methodological considerations 
In our studies, MIC susceptibility testing was performed with the plate agar 
diffusion method in a 5% CO2 atmosphere because 5-10% of pneumococcal 
isolates do not grow adequately in air (65, 117). CLSI guidelines, however, 
recommend broth microdilution and incubation in a normal atmosphere for 
pneumococcus. Both methods have been demonstrated to reliably to separate 
susceptible and resistant pneumococcal populations (117, 182, 273), although 
CO2 supplementation is known to elevate the MICs of pneumococci to 
macrolides and ketolides by approximately a one to three dilution, the effect 
of CO2 being perhaps most prominent for azithromycin (39, 65, 81, 192, 
348). However, because nearly all our pneumococcal isolates exceeding the 
macrolide or clindamycin non-susceptibility breakpoints had a macrolide 
resistance mechanism, we regard our results as reliable.   
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It is known that CO2 mainly affects pneumococci with a macrolide resistance 
mechanism, while only a slight increase in macrolide MICs is detected in 
wild type isolates (117, 182). For example, Fasola and co-workers observed 
that 5% of erythromycin-resistant and up to 43% of clindamycin-resistant 
pneumococci were misclassified into the wrong susceptibility category when 
incubation was performed in ambient air, but when incubated in CO2 the 
strains were clearly separated into susceptible and resistant categories, and 
the susceptible strains remained within the susceptible range (117). This 
result was also achieved when the incubation time in ambient air was 
extended from 24 hrs to 48 hrs. The authors concluded that the result was 
mainly due to the enhanced growth of resistant strains and earlier expression 
of resistance in CO2 rather than impaired antimicrobial activity, because only 
a small change in the pH of the culture media occurred in CO2 (117). 
Macrolides, ketolides and clindamycin are alkaline substances, the activities 
of which diminish in low pH conditions (191). CO2 has no significant effect 
on the MICs of other antimicrobials (61, 65, 180).  
Macrolide resistance mechanisms 
Efflux and methylase 
The mef gene was observed to be the most frequent macrolide resistance gene 
in Finland. The macrolide resistance gene distribution in pneumococci was 
very similar to that observed in 1999-2000 by Pihlajamaki and co workers 
(273). Finland’s macrolide resistance gene distribution is more comparable 
with North America and Scotland than continental Europe (8, 107, 170, 187, 
188, 358). In the USA, 66% of macrolide-resistant pneumococci carried the 
mef gene in 2000-2004 (187), while in Canada the proportion of mef-positive 
isolates from 1998-2004 was 47% (358). The mef gene is also the prevailing 
macrolide resistance mechanism in Australia, Germany, Greece, Ireland, the 
UK and the USA (107, 120). A recent study revealed that the erythromycin 
resistance MICs of mef-positive isolates are invading to the right (120), but 
this was not observed in our study, perhaps due to the low number of mef 
isolates in successive years and therefore the low statistical power.  
 
On the global level, erm(B) appears to be the most common macrolide 
resistance determinant in pneumococci. According to a recent study, its 
prevalence was 55% while the respective figure for the mef gene was 31% 
(107, 120). Countries with a high prevalence of the erm(B) gene include 
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Belgium (91%), France (90%), Spain (88%), Hungary (82%), Poland (80%), 
China (77%), Italy (56%) and Japan (58%) (107). Pneumococci carrying both 
mef and erm(B) have rapidly emerged within the last few years. The 
emergence of a dual resistance mechanism in pneumococci was first 
documented in 1999 in South Africa, where McGee and co-workers observed 
that 31% of macrolide-resistant pneumococci carried both of these genes and 
that the isolates were clonally related (233). The global prevalence of these 
isolates nearly doubled from 7% in 1999 (115) to 12% in 2004 (107). Today 
countries with a high prevalence of the double resistance mechanism in 
pneumococci (20-46%) include South Africa, South Korea, the USA, China 
and Australia (107). Our results suggest that the proportion of such isolates is 
rare in Finland. A dual mechanism was detected in five strains of macrolide-
resistant pneumococci in the MILL-TELI02 collection, and in only two 
isolates (0.9%) of the invasive pneumococcal collection in 2002-2006. 
Nevertheless, the spread of this genotype is of great concern and warrants 
careful monitoring. The vast majority of strains with a dual mechanism are 
multiresistant and clonally related, belonging to the widespread Taiwan19F-14 
clone (107, 187, 233) Moreover, it is alarming that pneumococci of this type 
are frequently isolated in 0- to 2-year-old children (107), which can increase 
the risk of treatment failures among this age group. The efflux determinant 
occurring simultaneously with the erm(B) gene seems to exclusively be the 
mef(E) subtype (8, 115). This was also the case in Finnish isolates. 
Interestingly, in a very recent congress abstract the presence of mef(A) was 
described together with erm(B) in pneumococci in Germany (34).  
 
erm(A) [subclass of erm(TR)] is a rare methylase mechanism in 
pneumococcus, but is frequently found in Streptococcus pyogenes (114, 201). 
In our study we found only one pneumococcal strain carrying this gene. 
Apart from Finland, erm(A) has been detected in individual pneumococcal 
strains from Greece, Belgium, the USA and Italy  (51, 111, 330, 344). 
mef subtypes 
According to our results, the majority of mef genes (70-90%) were of the 
mef(E) subtype and 10-30% were mef(A). Among other geographical regions, 
mef(E) appears to dominate in Canada, the USA, South Africa and Eastern 
Europe, whilst both mef(A) and mef(E) occur in Mediterranean and Western 
European countries (77). In Scotland, Italy and Norway, mef(A) has been 
observed to be the most common mef subtype, and its spread was clearly 
related to the emergence of the ST9 clone in these countries (8, 69, 86, 302). 
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The ST9 PMEN clone is also known as the erythromycin-resistant but 
penicillin-susceptible England14-9 clone (234).  mef(A) also seems to be 
frequent in Germany (34). We observed that invasive pneumococcal isolates 
carrying mef(A) possessed serotype 14 and shared an identical antibiogram. 
The latter applies also to mef(A) isolates of the MILL-TELI02 collection, but 
serotype information was not available. These results suggest that mef(A) 
strains are closely related and might be considered as indirect evidence of the 
presence of a penicillin-susceptible ST9 clone in Finland. Previous data have 
shown that the majority of reported ST9 clone members posses serotype 14 
(69). However, the presence of serotypes 3, 19A, 23F, 31, and 33A among 
the isolates belonging to ST9 suggest that this ST is prone to capsular switch 
(69). Tetracycline resistance in mef(A)-positive pneumococci has seldom 
been reported (69), but was observed in one strain of our study. It seems that 
the tetracycline resistance gene tet(M) occurs together with mef(A) in 
pneumococci (69), unlike in Streptococcus pyogenes, in which tet(O) has 
been reported with mef(A) (134).   
 
According to some investigators, the erythromycin MICs of mef(E) isolates 
are higher than those of mef(A) isolates (8), but this has not been confirmed 
(69). In our study a significant difference in ERY MICs between mef(A) and 
mef(E) isolates was observed in the first set of pneumococcal isolates, but not 
in the invasive isolates, although the geometric mean of the ERY MIC was to 
some extent higher in mef(A)-positive pneumococci of the latter collection.  
Ribosomal mutations 
The proportion of macrolide-resistant pneumococci carrying a ribosomal 
mutation was 6.4% (MILL-TELI02 collection). Of the erythromycin-resistant 
invasive isolates, 10% did not carry a macrolide resistance gene. Although 
these isolates were not screened for ribosomal mutations, phenotype data 
suggested the presence of mutation. These results are in accordance with 
Pihlajamaki and co-workers, who reported that 10% of invasive pneumococci 
had a ribosomal mutation or unknown mechanism in Finland in 1999-2000 
(273).  For some reason, macrolide resistance due to mutations seems to be 
more common in Finland than in many other countries. According to a 
European multicentre study including 8 European countries, the prevalence of 
ribosomal mutations was only 1% among erythromycin-resistant pneumococci 
(287). In Germany, 1.3% of 399 macrolide-resistant isolates had a ribosomal 
mutation (290), while in the Netherlands the respective figure was 5% (251) 
and in Belgium only 0.4%  (344). However, the last-mentioned Belgian result 
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was in contrast to the study by Farrell et al., who reported the prevalence of 
ribosomal mutations to be 6.8% among macrolide-resistant pneumococci in 
Belgium (107). In Canada ~ 4% of erythromycin-resistant pneumococci 
harboured a ribosomal mutation (358) and 6.5% in the USA (79), although in a 
later study the respective figure was 1.6% for the USA (107). Globally, the 
prevalence of ribosomal mutations was 1.9% in 2003-2004, ranging among 
countries from 0-18% (107). (Farrell et al., Int J AA, 2008). This is a slightly 
higher rate than reported in 1999-2000 (1.5%) by the same authors (108). 
Ribosomal mutations can also exist simultaneously with other resistance genes 
(288), as was illustrated in our study.  
 
Of all observed ribosomal mutations, A2059G seems to be the most common 
mutation converting macrolide resistance in pneumococci that are negative 
for common macrolide resistance determinant (92, 108, 288, 358). This was 
also the case in our study, although A2059C was previously more frequent in 
Finland (273, 275). Six novel mutations which, to our best knowledge, had 
not previously been described in pneumococci were found in this study. Two 
strains had a mutation in the highly conserved region 63LPWRQKGTGRAR74 
of the L4 protein. One of these had a glutamic acid (E) insertion after 
position 68, and the other strain had a glycine-glutamine-lycine (GQK) 
insertion after the same position. Earlier studies have suggested that 
mutations in this area are linked to macrolide resistance in pneumococcus 
(108, 275, 332). The role of the other four novel mutations, i.e. substitutions 
T94I and V205G in L4 or R22C and A101P in L22, remained unresolved. In 
particular, threonine replacement with isoleucine at position 94 in L4 could 
be significant, since threonine contains a reactive hydroxyl group, which is 
absent in the isoleucine molecule.  
 
5.2 Telithromycin 
Heterogeneous telithromycin resistance in pneumococci 
The main observation of this thesis was the presence of heterogeneous 
telithromycin resistance among pneumococci. In the first pneumococcal 
collection (MILL-TELI02), 26 pneumococcal isolates carrying erm(B) 
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expressed telithromycin resistance that was manifested by the presence of 
bacterial colonies inside the inhibition zone around the telithromycin disk. 
Heterogeneous telithromycin resistance was also detected in nine erm(B) 
isolates of the invasive pneumococcal collection in 2002-2006. This type of 
telithromycin resistance has not previously been described. The majority of 
pneumococcal isolates derived from the colonies growing inside the 
inhibition zone of telithromycin disks (i.e. zone isolates) showed high-level 
resistance to telithromycin in agar diffusion performed in a CO2-rich 
atmosphere. It was also evident that telithromycin resistance of the zone 
isolates was stable, homogeneous (consistent and clear growth pattern near 
telithromycin disk) and highly expressed (narrow inhibition zones and high 
MICs). Therefore, it can be concluded that some pneumococcal strains 
carrying erm(B) harbour a minor population of bacterial cells capable of 
expressing telithromycin resistance in vitro, which, according to 
telithromycin MICs, may be clinically significant. At least this characteristic 
can be considered to offer an advantage in the presence of antimicrobial 
pressure favouring the selection of resistant isolates. Previous laboratory 
experiments have shown that erm(B)-positive pneumococci require only two 
to three passages in telithromycin in order to achieve telithromycin resistance 
that is stable and maintained without continuing selective pressure from the 
antimicrobial agent (80, 349).  
 
The results of the agar dilution method used in this study were in accordance 
with the results of disk diffusion testing: the vast majority of isolates showing 
heterogeneous telihtromycin resistance in disk diffusion testing had a TEL 
MIC  2 mg/L according to the agar dilution method. It should be noted that 
telithromycin MIC  2 mg/L is a non-susceptibility breakpoint set by the 
CLSI for the broth dilution method performed in normal atmosphere due to 
which conclusions need to be drawn cautiously. When testing with the CLSI 
broth microdilution method, however, the majority of pneumococcal isolates 
showing heterogeneous resistance to telithromycin were classified as 
telithromycin susceptible. Therefore, this method might be considered as 
deficient in detecting this type of resistance in pneumococci. Furthermore, 
these results might indicate that the expression of telithromycin resistance is 
more efficient in the presence of CO2, as was considered by some authors to 
be the case with erythromycin and clindamycin (117). To conclude, we 
suggest that pneumococcal strains showing the MLSB phenotype, or known to 
be positive for erm(B), should not be considered as susceptible to 
telithromycin unless susceptibility testing, preferably with disk diffusion 
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method, is performed. It should also be further discussed and investigated 
whether the susceptibility testing of pneumococci in ambient air with existing 
breakpoints underestimates the occurrence of telithromycin resistance.  
The occurrence of telithromycin resistance  
Apart from 26 heteroresistant pneumococci, two mef-positive isolates were 
classified as non-susceptible to telithromycin due to the reduced diameter of 
the inhibition zone. If this result was extrapolated to the population of 1007 
pneumococci from which these isolates were derived, 2.8% of pneumococcal 
isolates in Finland were non-susceptible to telithromycin in 2002, the year in 
which telithromycin was launched on the market in Finland. Several studies 
in numerous countries have suggested the prevalence of telithromycin 
resistance to be less than 1% (110, 120, 229). One exceptional observation 
was from Taiwan, where Hsueh and colleagues reported that 16% of 936 
pneumococcal isolates had a telithromycin MIC  1 mg/L in 2000-2001 
(171). The majority of pneumococci with reduced telithromycin 
susceptibility in that study had an erythromycin MIC > 256 mg/L, which 
refers to the presence of erm(B) in the genome of these strains. Taiwan is a 
country with a very high rate of erythromycin resistance, and up to 94% of 
pneumococci are resistant to this agent (171). However, the methodology 
used in the Taiwanese study has subsequently been criticised (109). As 
mentioned previously, the PROTEKT study documented the worldwide 
prevalence of telithromycin resistance in pneumococci as being  0.3%, with 
no upward trend observed (120). A low prevalence of telithromycin 
resistance was also observed in USA: in 2001-2004, 0.01-0.04% of tested 
pneumococci were non-susceptible to telithromycin (187), while in 2005-
2006 the respective proportion was 0.6% (74). In Canada similar prevalence 
was reported for 2002 (283).  
 
Nevertheless, there are some signs of the emergence of telithromycin 
resistance, although so far the evidence has been restricted to individual case 
reports. To our best knowledge, the first clinical pneumococcal isolate 
resistant to telithromycin was described by Tait-Kamradt and co-workers in 
2001. The isolate had been derived from conjunctival discharge in a 1-year-
old boy in Canada as early as in 1996 (334). The first macrolide and 
fluoroquinolone treatment failure from which telithromycin-resistant 
pneumococcus was isolated was published in 2003 (271). According to this 
study, the development of telithromycin resistance (MIC 16 mg/L) during 
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clarithromycin and ciprofloxacin therapy appeared in a 71-year-old man in 
Spain in 2002. The cultured pneumococcal strain had an A2058G mutation in 
domain V of 23S rRNA in addition to a six amino acid (RTAHIT) insertion 
between amino acids T108 and V109 in the L22 protein. The isolate had ST180 
and possessed serotype 3. The patient was cured with vancomycin therapy 
(271). Two years later, two reports of telithromycin treatment failures were 
published (106, 135). In one of these reports the patient was an 87-year-old 
woman with pneumococcal pneumonia who had chronic obstructive 
pulmonary disease as an underlying disorder together with a history of 
several treatments with macrolides. Telithromycin therapy was started but the 
patient’s condition worsened. Bacteriological culture yielded a 
pneumococcus expressing TEL MICs of 1 mg/L in ambient air, but, 
interestingly, 8 mg/L when incubated in a CO2-enriched atmosphere. The 
isolate had reduced susceptibility to penicillin in addition to resistance to 
macrolides, lincosamides, trimethoprim-sulfonamides and tetracycline. The 
patient recovered after telithromycin was replaced with amoxicillin (135). 
The other report described a treatment failure and the development of 
telithromycin resistance during telithromycin therapy in a 29-year-old woman 
who had acute exacerbation of chronic bronchitis (106). Azithromycin 
therapy was initiated, but was switched a few days later to telithromycin 
based on susceptibility testing. In the initial testing the pneumococcal isolate 
showed resistance to fluoroquinolones, penicillin and an M phenotype to 
macrolides (ERY MIC = 16 mg/L and AZM MIC = 32 mg/L), but was 
susceptible to telithromycin, showing MICs of 0.12 mg/L and 0.25 mg/L, 
respectively, in a normal atmosphere and in CO2. The patient intially 
responded well to telithromycin therapy but her condition later worsened. 
This time the telithromycin MICs of the bacterial isolate were 256 mg/L and 
512 mg/L by the agar dilution and broth dilution method, respectively, in a 
normal atmosphere, but in CO2 it was 1024 mg/L. The later isolate had a 
constitutive MLSB phenotype, although both the previous and the later isolate 
carried the mef(E) gene. Both isolates also had an S20N substitution in L4 
compared to a wild type R6 S. pneumoniae strain. Further studies revealed, 
however, that the later isolate had an A2058T mutation in domain V of 23S 
rRNA and a three amino acid 98PIN102 deletion in the L22 protein, which 
were missing in the previous isolate. Both the previous and the later isolates 
were identical in PFGE analysis and had the same mutations in gyrA, gyrB, 
parC and parE genes conferring fluoroquinolone resistance (106). 
Laboratory observations have provided evidence that telithromycin is only 
bacteriostatic against pneumococci with erm(B) (4, 202) and that 
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telithromycin concentration in lung tissue is not sufficient to kill 
pneumococci with an elevated MIC (2-8 mg/L) to telithromycin (4). 
Although telithromycin treatment failures still seem to be rare, the use of 
telithromycin in treating pneumococcal infections caused by a macrolide-
resistant isolate should be carefully considered and at least susceptibility 
testing should be performed prior to treatment. In the case of an unfavourable 
response to telithromycin therapy, new specimens should be taken to rule out 
the presence of telithromycin-resistant pneumococci, because isolates with a 
macrolide resistance mechanism are prone to develop high-level resistance 
during treatment. 
Telithromycin resistance mechanisms 
According to laboratory experiments, telithromycin MICs of A2059G, 
C2610U or C2611U laboratory-derived mutants did not differ from wild type 
isolates, whilst strains having an A2058U mutation had a slightly elevated 
telithromycin MIC (0.25-1 mg/L) and a mutant with an A752 deletion had a 
telithromycin MIC of 4 mg/L (52). Apart from interaction at position A2058 
in domain V, telithromycin interacts at nucleotide A752 in domain II of 23S 
rRNA, which improves the drug’s affinity to resistant ribosomes (1). 
Therefore, changes at this position can reduce the susceptibility to 
telithromycin. Laboratory experiments have shown that a high telithromycin 
MIC in pneumococcus can be obtained after serial passage of an erm(B)-
positive isolate to telithromycin (349). In one of such isolates with a 
telithromycin MIC > 32 mg/L a 210 bp deletion was observed in the 
upstream region of erm(B) together with an L94Q change in the L22 protein. 
Interestingly, the same study described telithromycin-resistant pneumococci 
in which no deletions in the regulatory sequence of erm(B) or ribosomal 
mutations could be detected (349).  
 
In clinical isolates, telithromycin MICs of 1-16 mg/L have been detected in 
pneumococcal isolates having a 71REKGTG72 insertion in the L4 protein 
(3.12 mg/L), a 108RTAHIT109 insertion in the L22 protein (1 mg/L), a K68Q 
mutation in the L22 protein (1 mg/L), an A2058G mutation together with a 
108RTAHIT109 insertion in the L22 protein (8-16 mg/L) and a 92VRPR93 
insertion in the L22 protein (2 mg/L) (see Table 1). Slightly increased 
telithromycin MICs have also been reported in association with other 
mutations. For example, in a Finnish study, four isolates with an A2059C 
mutation had a telithromycin MIC of 0.125 mg/L, but isolates with an 
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A2059G or mutation alone or combined with a 69GTG71 to TPS mutation had 
a telithromycin MIC of 0.25 mg/L and 0.5 mg/L, respectively (275). It seems, 
however, that higher telithromycin resistance is especially associated with the 
presence of erm(B) in pneumococci and deletions detected in the erm(B) 
leader sequence or the SD2 site of erm(B) (166, 360). Such changes can also 
occur with a combination of a 69GTG71 to TPS mutation in ribosomal protein 
L4 (360, 362). It is known that ketolide resistance in Streptococcus pyogenes 
correlates with the degree of dimethylation by Erm and that a strain with a 
deletion in the erm(B) leader sequence leads to high degree of dimethylation 
(95). Recently, this was also shown to be a case in S. pneumoniae (360). In 
our study, both parent and zone isolates had identical erm(B), 23S rRNA, 
L22 and L4 sequences. We could not find deletions in the erm(B) leader 
sequence or mutations known to confer macrolide or ketolide resistance in 
these isolates (paper III). 
Clonal relationship of the telithromycin resistant isolates  
Our results demonstrated that the capability of expressing heterogeneous 
resistance can be detected in several pneumococcal strains. Altogether, seven 
distinct sequence types that had this capacity were identified. The most 
common telithromycin resistant strain in our study, ST193, is a 19A serotype 
variant of the PMEN clone Greece21-30. This clone has earlier been described 
in Greece, Brazil, the United Kingdom, Vietnam and Italy (133, 329). Apart 
from Finland, serotype variant 19A of this clone has been observed in Italy. 
Otherwise, the serotypes of the members of this clone have been reported to 
possess serotypes 21, 18C, 14, or are non-typeable (www.mlst.net). ST133 
has previously been reported in Spain with the same serotype as our two 
strains, 18C (www.mlst.net). Two other strains described in our study were 
representatives of well-characterised PMEN clones. One of these had ST273, 
which is a representative of the penicillin-susceptible but erythromycin-
resistant PMEN global clone Greece6B-22. Apart from Greece, this clone has 
been detected in Iceland, Israel, Portugal, Italy, Germany and Switzerland 
(www.mlst.net). The other strain having ST271 was a single locus variant of 
a multi-drug-resistant Taiwanese19F clone, the sequence type of which is 236 
(45). Our isolate carried both erm(B) and mef(E) macrolide resistance 
determinants. The same variant has spread worldwide: according to an 
international study, over 85% of pneumococcal isolates having the double 
mechanism belonged to one major clonal complex representing ST271 (115). 
Our second isolate with the double mechanism had a novel sequence type, 
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ST2248. Two other novel sequence types, ST2306 and 2307 with serotypes 
14 and 19F, respectively, were also observed.  
5.3 Resistance to other antimicrobials 
Penicillin 
A continuous increase in penicillin non-susceptibility from 8 to 16% was 
observed among invasive pneumococci during the four-year study period. 
Compared to 1999-2000, a four-fold increase was observed in penicillin non-
susceptibility among invasive pneumococci in Finland (273). As in the case 
of erythromycin resistance, the highest penicillin non-susceptibility rates 
were detected in children. Regarding penicillin non-susceptibility, the 
European map is very similar to that for erythromycin resistance, with south-
western Europe and Mediterranean regions being the resistance hot-spots, 
although penicillin non-susceptibility prevalences are to some extent lower 
than those for erythromycin (293). France and Spain are at top of the list of 
European countries with the highest penicillin non-susceptibility (84, 258, 
287, 293). In Spain, however, a decline in overall penicillin non-
susceptibility from 39.5 to 33% was observed during 2001-2003, the decline 
being largest in children under 14 years old, from 60.4 to 41.2% (258). The 
authors suggested that increased vaccination of children with the PCV-7 as 
well as reduced antimicrobial consumption in the community could be the 
possible explanatory factors for this trend (258). In Portugal, the proportion 
of pneumococci intermediately susceptible to penicillin increased from 12 to 
23% in 1994-2004 with a simultaneous decrease (from 4 to 0.9%) in the 
proportion of isolates showing high level penicillin resistance (90). A study 
from the USA also reported a change towards intermediate resistance: in 
2000-2004 the proportion of intermediately resistant isolates increased from 
12.5% to 20% while the proportion of resistant isolates decreased from 
26.3% to 16.5% (187). 
 
Regardless of the overall high penicillin non-susceptibility percentages in 
many European countries, some countries such as Denmark, Sweden, 
Norway, Iceland, the Netherlands and the UK have so far managed to keep 
penicillin non-susceptibility prevalences between 0-10% (46, 293). In 
Canada, 15% of pneumococci were penicillin non-susceptible in 2002 and 
approximately half of these isolates expressed a high level of penicillin 
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resistance (283). In the USA, on the other hand, the proportion of penicillin 
non-susceptible isolates exceeded 37% in 2005-2006, and 16% of all 
pneumococci are fully resistant to penicillin (74). Overall, on the global level, 
penicillin non-susceptibility remained at 37% in 2001-2004, with wide 
variation among countries (120). The worldwide prevalence of pneumococci 
fully resistant to penicillin (~24%) exceeds that of intermediate isolates 
(~14%) (120). In this context, the situation in Finland is good, since only 4% 
percent of pneumococci are fully resistant to penicillin.  
 
The penicillin-resistant invasive pneumococcal population in Finland seems 
to be genetically rather heterogeneous. Several international PMEN clones 
with their variants with different type of macrolide rsistance genes, as well as 
strains with new sequence types were detected, indicating the continuous 
exchange of genetic material between the pneumococcal isolates as well as 
the liability and competence of these isolates. The factors affecting clonal 
survival are complex and not fully understood. They can include 
antimicrobial use, the development of herd immunity (i.e. use of vaccines), 
and characteristics of the strain itself (14, 315, 316), including virulence 
factors. The most frequent clone detected in Finland, Spain9V-3 or ST156, 
has been observed to be one of the most successful global clones (133, 150, 
306, 315, 366). This clone was recently found to be associated with 
increasing penicillin resistance in Sweden (315). The Swedish study group 
also proved that members of this clone carried a rlrA pilus islet that was 
shown to make the clone more successful in an animal model of carriage 
compared to the strains that lack this gene (315). The pilus gene was also 
found in ST156 isolates of our study.    
Ceftriaxone 
Penicillin non-susceptible pneumococci are often still susceptible to second 
or third generation cephalosporins, although MICs are higher compared to 
penicillin susceptible strains (38, 265). However, the susceptibility of 
penicillin-resistant pneumococci to cephalosporins is difficult to predict and 
should therefore always be tested. It is also possible for an isolate to have a 
high MIC to cephalosporins and just a slightly elevated MIC to penicillin. 
This type of isolate was already described at the beginning of the 1990s 
(124). It seems that ceftriaxone-resistant strains are extremely rare in Finland, 
possibly due to the relatively low proportion of pneumococci that are highly 
resistant to penicillin. However, reduced susceptibility was detected in 3-4% 
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of isolates, which warrants careful surveillance in the future. Ceftriaxone 
non-susceptibility is more frequent in countries with a high prevalence of 
penicillin resistance. In South Korea and Singapore > 15% of pneumococci 
were non-susceptible to ceftriaxone in the late 1990s and early 2000s (62, 
208). In Taiwan, the prevalence of ceftriaxone non-susceptibilty increased 
from 3-4% (before 2004) to 7.4% (by 2005) (60). In North-America in 1998-
2004, 6.3% of pneumococci were non-susceptible to ceftriaxone, but the 
MIC90 was low, 1 mg/L (195). In Brazil, high level ceftriaxone resistance 
(MIC  4) was also low (0.5%) for the same period (53). In Portugal, 
ceftriaxone non-susceptibility was observed to decrease from 4% to < 1% in 
1994-2006 when a shift from penicillin resistance to penicillin intermediate 
susceptibility was observed (90). In the Barcelona area of Spain, non-
susceptibility to ceftriaxone was recently reported as 9% (343). In Italy, 
nearly all pneumococci (99.9%) were susceptible to ceftriaxone in the period 
from 1993-2004 (244). In Hungary, a slightly lower susceptibility rate (99%) 
was reported in 1998-2004 (145). In Canada, only a few isolates were non-
susceptible to ceftriaxone in 2002 (283). This was in contrast to another 
Canadian study that documented 5% ceftriaxone non-suceptibility among 
pediatric isolates, the majority of which were fully resistant to penicillin (27). 
In Greece, 1% of pneumococci recovered from carriers under 6 years old 
were non-susceptible to ceftriaxone, while the respective figure for adult 
clinical isolates was 5.6%. The proportions of isolates showing full resistance 
to ceftriaxone were 0.1 and 2.2%, respectively (282).  It must be noted 
however, that the comparison between the studies is sometimes difficult 
because of differences in representativeness of the investigated isolates, used 
breakpoints and other methods.   
 
Fluoroquinolones 
 Fluoroquinolone resistance is rare in Finland ( 0.5%) and no increasing 
trend was observed. In Europen countries, 1-2% of pneumococci were 
reported to be resistant to fluoroquinolones in 2004-2005 (90 , 91, 287). It 
has also been speculated that fluoroquinolone resistance would emerge rather 
slowly due to the possible fitness cost of the resistance to bacterial cells 
(300). However, in Italy, up to 15% of pneumococci were resistant to 
ciprofloxacin and 5.6% to levofloxacin in a multicentre study that 
investigated bacterial strains collected in 2001-2004 (87). In Canada an 
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increasing trend in ciprofloxacin resistance from < 1% in 1997 to 4.2% in 
2005 was also observed (Adam et al., AAC, 2007, 51, 198-207). A similar 
observation was reported in Portugal: from 0.5% ciprofloxacin resistance in 
2002 to 3.5% in 2004 (90).  
Multiresistance  
 
In our study over 70% of PNSP isolates of this study were also non-
susceptible to erythromycin. It seems that this proportion has increased to 
some extent compared to year 2000 when 62% of PNSP isolates were 
erythromycin non-susceptible (274). However, due to relatively low 
proportion of resistance to other antimicrobials, multiresistance situation is 
still satisfactory in Finland, particularly what comes to invasice isolates. For 
comparison, In Portugal the prevalence of multiresistace in invasive 
pneumococci increased from 4% to 15.6% in 1994-2004, paraller with the 
increase of tetracycline and erythromycin resistance (90).  In general, the 
higher resistance to erythromycin or penicillin in pneumococci, the higher 
prevalence of multiresistance is detected. For example in USA 
multiresistance percentages ranges from 9 to 25% by region with the highest 
rates detected in those areas with high prevalence of penicillin and 
erythromycin resistant strains(74, 187).  
 
 
5.4 Spread and control of resistance 
 
The clonal spread of resistant strains seems to be efficient in pneumococci 
(12, 83, 250). In Finland the majority of penicillin-resistant pneumococci also 
belong to well-known global clones, although the number of clones is quite 
high. In addition, new variants and novel sequence types indicate the 
continous exchange of genetic material between pneumococci. This is also 
reflected by the presence of different types of resistance genes in strains of 
the same sequence type.  
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Apart from clonal spread, many studies have shown that the higher the 
antimicrobial pressure, the greater the resistance in pneumococci (25, 35, 89, 
200, 293). This was also clearly illustrated in a study including 
pneumococcal resistance data and antimicrobial consumption data from 15 
European countries (293). Compared to other European countries, Finland 
had a medium level of antimicrobial consumption (~ 17 DDD per 1000 
inhabitants), the range being 9.7-31.6 DDDs in 1998-2004. Antimicrobial use 
was highest in France and lowest in the Netherlands (293). As earlier 
reviewed, these countries have the highest and the lowest antimicrobial 
prevalence, respectively. The Nordic countries represented in this study had a 
lower overall consumption of antimicrobials than Finland. In the light of this 
information, it is not surprising that Finland is a leading country in Northern 
Europe in terms of resistance rates.  
 
However, even though it is widely accepted that resistance and consumption 
are linked, the magnitude of the relationship is not always clear. A reduction 
in antimicrobial consumption does not always result in a reduction in 
resistance. For example, due to the worrying evolution of resistance in the 
1990s, public health authorities in the UK and Ireland launched campaigns to 
raise awareness of antimicrobial resistance (221). As a consequence, the total 
sales per capita of erythromycin and betalactams decreased significantly from 
1994-2004 in the UK, but not in Ireland. This was followed by decrease in 
penicillin non-susceptibility among pneumococci in both countries, while 
macrolide resistance remained rather stable (221). In Canada, the emergence 
of high-level penicillin resistance and multiresistance was observed in 1997-
2002, despite a decrease in antimicrobial consumption (369). In Iceland, 
meanwhile, an increase in PNSP in healthy carriers was observed in some 
regions, although the consumption of antimicrobials decreased after active 
public health intervention (12). In Norway, on the other hand, macrolide 
resistance increased despite low macrolide consumption in 2001-2005 (319). 
These examples are interesting and raise questions such as the following: 1) 
Why is a decrease in resistance associated with reduced consumption for one 
antimicrobial (betalactam consumption decrease – penicillin non-
susceptibility decrease), but not necessarily for another (erythromycin 
consumption decrease – erythromycin resistance stable)? 2) Why does the 
resistance to one antimicrobial decrease but that to another remain stable, 
even though their consumption does not change? 3) How large a decrease in 
consumption and how long a duration of action is needed before the effect on 
resistance rates can be seen for each antimicrobial? 4) What is the effect of 
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the starting level of resistance (low vs. medium vs. high) on resistance trends 
when a follow-up period is started? Finally, 5) How long a follow-up period 
is needed before any conclusions about trends can be made (many studies 
calculate statistical parameters for a short follow-up period)?  
 
It has been suggested that to reduce the antimicrobial prevalence in 
pneumococcus, a large reduction in antimicrobial consumption is needed on 
the population level (237).  Apparently, many other factors also affect 
resistant rates such as population density, age, geographical location, isolate 
source (345), herd immunity, pneumococcal population dynamics, the clonal 
spread of resistant isolates (12, 319) and socioeconomic factors (131). 
Furthermore, the importance of taking pharmacokinetic and 
pharmacodynamic parameters into account to confirm the bacteriological 
cure and to avoid the selection of resistant isolates when treating infections in 
individual patients should not been underestimated. To summarise, in 
controlling antimicrobial resistance, a multidisciplinary approach is therefore 
needed that includes continous surveillance, education and feedback, the use 
of vaccines and the development of new drugs.  
 
5.5 Resistance in relation to conjugate vaccine serotypes  
Regardless of the fact that there has been considerable surveillance and 
research activity over the years, and regardless of the many specialists and 
committees expressing their concerns, respective actions and interventions to 
control the resistance problem have, in general, been too deficient to have an 
effect.  However, the 7-valent vaccine has had a dramatic effect in reducing 
the incidence of invasive pneumococcal disease, not only in children but also 
in other age groups, due to heard-immunity (280). In some places, a decrease 
in resistance has also occurred after launching the vaccine. According to a 
recent evaluation, a group of experts decided to recommend the introduction 
of this vaccine in the Finnish national vaccination schedule (KTL 2009, 
http://www.ktl.fi/portal/2920). Our results showed that the approximate 
hypothetical serotype coverage by PCV-7 was 58%, ranging from 54% 
(2003) to 62% (2006). This result is in accordance with many others (236, 
282). In Finland the conjugate vaccine would cover 80% of the erythromycin 
resistant and 86% of the penicillin non-susceptible isolates. The serotypes 
most frequently non-susceptible to erythromycin or penicillin in Finland were 
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14, 9V, 19A, 6B and 19F, as in many other countries (20, 50, 83, 121, 220, 
350). Serotype 23F was the third most common serotype among invasive 
isolates, but the proportion of resistant isolates in this serotype was relatively 
low compared to other reports. Serotype 23F has been shown to be frequent 
among resistant isolates elsewhere (50, 227, 278).  
 
Regardless of the conjugate vaccine’s outstanding positive effect on the 
incidence of invasive pneumococcal disease, there are some concerns. 
Several studies have documented that the invasive pneumococcal disease 
caused by either non-vaccine serotypes (particularly serotypes 35B, 15C, 
15B, and 33F) or vaccine-related serotypes (particulary 19A) has increased in 
the post-vaccine era (136). The reduction of pneumococci of vaccine 
serotypes forms a free ecological niche to be filled by non-vaccine and 
vaccine-related pneumococci. This can occur by 1) the expansion of clones of 
non-vaccine/vaccine-related serotypes that were a minority in the pre-vaccine 
era (129), 2) the maintenance/emergence of existing clones that switch their 
vaccine serotype capsule to a non-vaccine or vaccine-related serotype by 
capsular switch (=same sequence types remain, only the capsular type they 
posess changes) (261) or 3) by the recombination of genetic material and the 
generation of new clones (148).      
 
Because of the high prevalence of antimicrobial resistance in most common 
pneumococcal serotypes, one could expect the introduction of the PCV-7 into 
the national vaccination programme would reduce the proportion of 
antimicrobial resistance in Finland. Follow-up studies performed in the post-
vaccination era suggest, however, that the longer term impact of the vaccine 
on the epidemiology of antimicrobial resistance is not yet clear. Some 
investigators have observed a reduction in antimicrobial resistance (32, 230, 
335), while others have not (89, 129, 236, 238). Current evidence suggestes 
that the prevalence of antimicrobial resistance can rapidly increase in non-
vaccine/vaccine related pneumococci (112, 172). The data also indicate that 
the PCV-7 does not reduce the overall pneumococcal carrier rate in children 
or antimicrobial resistance among these isolates (172, 216, 268). This is 
probably because the vaccine serotypes are replaced by non-vaccine or 
vaccine-related serotypes due to capsular switching, while the genotype 
remains same (136, 148, 249, 314, 322). The introduction of the 
pneumococcal vaccine into the national vaccination schedule in Finland will 
certainly affect pneumococcal epidemiology. The future will reveal whether 
this will have an impact on antimicrobial resistance. Emerging macrolide and 
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penicillin resistance in pneumococci is a public health concern and may 
create problems in the treatment of pneumococcal infections. Therefore close 
surveillance of antimicrobial resistance and of changes in the pneumococcal 
population is of utmost importance in the near future.   
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6. Conclusions 
 
1. There is a high prevalence of erythromycin resistance in Finland since nearly 
30% of all pneumococci and 46% of pneumococci of small children are non-
susceptible to erythromycin. Therefore macrolides can not be recommended 
for the treatment of pneumococcal infections without susceptibility testing to 
avoid possible treatment failures.  
 
2. The main observation of this thesis was the presence of heterogeneous 
telithromycin resistance among pneumococci carrying erm(B). Such isolates 
harbour a minor population of bacterial cells capable of expressing high level 
telithromycin resistance in vitro, which may be clinically significant. 
However, CLSI broth microdilution method does not favour the detection of 
pneumococci with this resistance type. Therefore disk diffusion susceptibility 
testing of erm(B) positive pneumococci or pneumococci showing MLSB 
phenotype is recommended.  
 
3. The presence of more than one clone among telithromycin resistant 
pneumococci suggests that the capability to express telithromycin resistance 
have developed independently in separate ancestors. The results also indicate 
that this type of resistance have capability to spread, since the majority of 
such isolates belonged to global clones.  
 
4. Prior its widespread use, the proportion of telithromycin resistant isolates was 
rather high (2.6%) in Finland if compared to other studies. Partly this can be 
explained by the use of different methodology, but because the similar result 
was achieved with two different methods in this study, we consider our result 
as reliable. Close monitoring of telithromycin resistance is needed in the future.  
 
5. Apart from macrolide resistance, also proportion of penicillin non-susceptible 
isolates is emerging, being already 16% in 2006. However, the prevalence of 
isolates fully resistant to penicillin is still low. The results showed that there 
are several international PMEN clones and their new variants indicating 
which continuous exchange of genetic material between the strains. Our 
results provide baseline information on pneumococcal epidemiology of the 
prevaccine era and allow the follow-up changes which occur in 
pneumococcal population after the PCV-7 vaccine is introduced.  
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